US20200138982A1 - Radioactive probe for detecting hydrogen sulfide - Google Patents
Radioactive probe for detecting hydrogen sulfide Download PDFInfo
- Publication number
- US20200138982A1 US20200138982A1 US16/730,029 US201916730029A US2020138982A1 US 20200138982 A1 US20200138982 A1 US 20200138982A1 US 201916730029 A US201916730029 A US 201916730029A US 2020138982 A1 US2020138982 A1 US 2020138982A1
- Authority
- US
- United States
- Prior art keywords
- hydrogen sulfide
- complex compound
- imaging
- detecting
- present disclosure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 title claims abstract description 136
- 229910000037 hydrogen sulfide Inorganic materials 0.000 title claims abstract description 133
- 239000000523 sample Substances 0.000 title claims abstract description 48
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 165
- 238000003384 imaging method Methods 0.000 claims abstract description 71
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 239000010949 copper Substances 0.000 claims description 181
- 239000000126 substance Substances 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 30
- 208000010125 myocardial infarction Diseases 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 14
- 206010003246 arthritis Diseases 0.000 claims description 13
- 206010040047 Sepsis Diseases 0.000 claims description 11
- 238000012634 optical imaging Methods 0.000 claims description 11
- 238000002600 positron emission tomography Methods 0.000 claims description 11
- 206010033645 Pancreatitis Diseases 0.000 claims description 9
- 239000002872 contrast media Substances 0.000 claims description 9
- 125000006824 (C1-C6) dialkyl amine group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 238000002591 computed tomography Methods 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 150000003973 alkyl amines Chemical class 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 230000005466 cherenkov radiation Effects 0.000 claims description 5
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- LUWXUZOUEIGWRY-UHFFFAOYSA-N 3-methyl-1,4,7,10-tetrazacyclotridecane Chemical compound CC1CNCCCNCCNCCN1 LUWXUZOUEIGWRY-UHFFFAOYSA-N 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 210000002744 extracellular matrix Anatomy 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- 201000011475 meningoencephalitis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 201000004537 pyelitis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 10
- 238000009206 nuclear medicine Methods 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 8
- 238000010171 animal model Methods 0.000 abstract description 7
- 230000003287 optical effect Effects 0.000 abstract description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 26
- 241000700159 Rattus Species 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 23
- 206010061218 Inflammation Diseases 0.000 description 19
- 230000004054 inflammatory process Effects 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 17
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- -1 sulfide ions Chemical class 0.000 description 11
- 0 [1*]N12*C3([2*])C([6*])[C@H]([7*])C4([3*])BC([4*])(C([8*])[C@@H]1[5*])[Cu]342 Chemical compound [1*]N12*C3([2*])C([6*])[C@H]([7*])C4([3*])BC([4*])(C([8*])[C@@H]1[5*])[Cu]342 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000005526 G1 to G0 transition Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 9
- 229960003180 glutathione Drugs 0.000 description 8
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 5
- 238000012879 PET imaging Methods 0.000 description 5
- 238000004896 high resolution mass spectrometry Methods 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 208000025698 brain inflammatory disease Diseases 0.000 description 4
- 230000004700 cellular uptake Effects 0.000 description 4
- 229910001431 copper ion Inorganic materials 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 206010014599 encephalitis Diseases 0.000 description 4
- 239000012216 imaging agent Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- QTJYRCWQWQLZKK-UHFFFAOYSA-N 1,4,7-trihexadecyl-1,4,7-triazonane Chemical compound C(CCCCCCCCCCCCCCC)N1CCN(CCN(CC1)CCCCCCCCCCCCCCCC)CCCCCCCCCCCCCCCC QTJYRCWQWQLZKK-UHFFFAOYSA-N 0.000 description 3
- WLDGDTPNAKWAIR-UHFFFAOYSA-N 1,4,7-trimethyl-1,4,7-triazonane Chemical compound CN1CCN(C)CCN(C)CC1 WLDGDTPNAKWAIR-UHFFFAOYSA-N 0.000 description 3
- KPMQUEDRVYIRKH-UHFFFAOYSA-N 1,4,7-tris(anthracen-9-ylmethyl)-1,4,7-triazonane Chemical compound C1=CC=CC2=CC3=CC=CC=C3C(=C12)CN1CCN(CCN(CC1)CC=1C2=CC=CC=C2C=C2C=CC=CC=12)CC=1C2=CC=CC=C2C=C2C=CC=CC=12 KPMQUEDRVYIRKH-UHFFFAOYSA-N 0.000 description 3
- NUPGMEYEZNUVEF-UHFFFAOYSA-N 1-methyl-1,4,7-triazonane Chemical compound CN1CCNCCNCC1 NUPGMEYEZNUVEF-UHFFFAOYSA-N 0.000 description 3
- 102100021908 3-mercaptopyruvate sulfurtransferase Human genes 0.000 description 3
- 108030003918 3-mercaptopyruvate sulfurtransferases Proteins 0.000 description 3
- PCVRSXXPGXRVEZ-UHFFFAOYSA-N 9-(chloromethyl)anthracene Chemical compound C1=CC=C2C(CCl)=C(C=CC=C3)C3=CC2=C1 PCVRSXXPGXRVEZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- QAYLIUAEJIOQBX-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)N1CCNCCNCC1 Chemical compound C(CCCCCCCCCCCCCCC)N1CCNCCNCC1 QAYLIUAEJIOQBX-UHFFFAOYSA-N 0.000 description 3
- SBLUHRDDGCZVEA-UHFFFAOYSA-N C1=CC=CC2=CC3=CC=CC=C3C(=C12)CN1CCNCCNCC1 Chemical compound C1=CC=CC2=CC3=CC=CC=C3C(=C12)CN1CCNCCNCC1 SBLUHRDDGCZVEA-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- SIKFMTBMPJGUFS-UHFFFAOYSA-N 1,4,7,10-tetrakis(anthracen-9-ylmethyl)-1,4,7,10-tetrazacyclododecane Chemical compound C1=CC=CC2=CC3=CC=CC=C3C(=C12)CN1CCN(CCN(CCN(CC1)CC=1C2=CC=CC=C2C=C2C=CC=CC=12)CC=1C2=CC=CC=C2C=C2C=CC=CC=12)CC=1C2=CC=CC=C2C=C2C=CC=CC=12 SIKFMTBMPJGUFS-UHFFFAOYSA-N 0.000 description 2
- PQKVTLPUUMJPPI-UHFFFAOYSA-N 1,4,7-trithia-10-azacyclododecane Chemical compound C1CSCCSCCSCCN1 PQKVTLPUUMJPPI-UHFFFAOYSA-N 0.000 description 2
- ZKUNQWHOSLDGBP-UHFFFAOYSA-N 1-(anthracen-9-ylmethyl)-1,4,7,10-tetrazacyclododecane Chemical compound C=12C=CC=CC2=CC2=CC=CC=C2C=1CN1CCNCCNCCNCC1 ZKUNQWHOSLDGBP-UHFFFAOYSA-N 0.000 description 2
- HNTGIJLWHDPAFN-UHFFFAOYSA-N 1-bromohexadecane Chemical compound CCCCCCCCCCCCCCCCBr HNTGIJLWHDPAFN-UHFFFAOYSA-N 0.000 description 2
- KXZQYLBVMZGIKC-UHFFFAOYSA-N 1-pyridin-2-yl-n-(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=CC=NC=1CNCC1=CC=CC=N1 KXZQYLBVMZGIKC-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- BQUWOMZDYJYZOM-SUZBSDSCSA-N C/C1=N2\C(C)CN3C(C)(C)C/C(C)=N4/C(C)CN(C(C)(C)C1)[Cu]324.C1=CC(CN23CCN4CCCN5CCN(CC2)[Cu]543)=CC=C1CN12CCN3CCCN4CCN(CC1)[Cu]432.CC1CC(C)(C)N2CCN3C(C)CC(C)(C)N4CCN1[Cu]342.CC1CCN2C3CCCCC3N3C(C)CCN4C5CCCCC5N1[Cu]423.CCOC(=O)CCN12CCN3CCN4CCN(CC1)[Cu]432.C[C@H]1CC(C)(C)N2CCN3[C@@H](C)CC(C)(C)N4CCN1[Cu]342 Chemical compound C/C1=N2\C(C)CN3C(C)(C)C/C(C)=N4/C(C)CN(C(C)(C)C1)[Cu]324.C1=CC(CN23CCN4CCCN5CCN(CC2)[Cu]543)=CC=C1CN12CCN3CCCN4CCN(CC1)[Cu]432.CC1CC(C)(C)N2CCN3C(C)CC(C)(C)N4CCN1[Cu]342.CC1CCN2C3CCCCC3N3C(C)CCN4C5CCCCC5N1[Cu]423.CCOC(=O)CCN12CCN3CCN4CCN(CC1)[Cu]432.C[C@H]1CC(C)(C)N2CCN3[C@@H](C)CC(C)(C)N4CCN1[Cu]342 BQUWOMZDYJYZOM-SUZBSDSCSA-N 0.000 description 2
- XQGSRWYSUXITRF-PFUBTCLUSA-N C1=CC2=CC3=C(C=CC=C3)C(CN34CCN5(CC6=C7C=CC=CC7=CC7=C6C=CC=C7)CCN6(CC7=C8C=CC=CC8=CC8=C7C=CC=C8)CCN(CC7=C8C=CC=CC8=CC8=C7C=CC=C8)(CC3)[Cu]456)=C2C=C1.C1=CC2=CC3=C(C=CC=C3)C(CN34CCN5CCN6CCN(CC3)[Cu]654)=C2C=C1.C1CN2CCN3CCN4CCN1[Cu]243.C1CO2CCN3CCO4CCN1[Cu]324.C[C@H]1CC(C)(C)N2CCN3[C@H](C)CC(C)(C)N4CCN1[Cu]324 Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN34CCN5(CC6=C7C=CC=CC7=CC7=C6C=CC=C7)CCN6(CC7=C8C=CC=CC8=CC8=C7C=CC=C8)CCN(CC7=C8C=CC=CC8=CC8=C7C=CC=C8)(CC3)[Cu]456)=C2C=C1.C1=CC2=CC3=C(C=CC=C3)C(CN34CCN5CCN6CCN(CC3)[Cu]654)=C2C=C1.C1CN2CCN3CCN4CCN1[Cu]243.C1CO2CCN3CCO4CCN1[Cu]324.C[C@H]1CC(C)(C)N2CCN3[C@H](C)CC(C)(C)N4CCN1[Cu]324 XQGSRWYSUXITRF-PFUBTCLUSA-N 0.000 description 2
- GAICUQHMMOBKJK-DWVKLTIVSA-M C1CN2CCN3CCCN4CCN(C1)[Cu]234.C1CN2CCN3CCN4CCN(C1)[Cu]234.CC1=CC=C(CC2CN3CCN4CCN5CCN2[Cu]453)C=C1.CC1=CC=CC2=C(S(=O)(=O)N34CCN5CCN6CCN(CC3)[Cu]654)C=CC=C12.CNC1=NN2=C(C)C(C)=N3/C=C(/NC)N(C)[Cu]32S1.C[C@@H]1C(CO)O[C@@H](N23CCN4CCN5CCN(CC2)[Cu]543)C(O)[C@H]1O Chemical compound C1CN2CCN3CCCN4CCN(C1)[Cu]234.C1CN2CCN3CCN4CCN(C1)[Cu]234.CC1=CC=C(CC2CN3CCN4CCN5CCN2[Cu]453)C=C1.CC1=CC=CC2=C(S(=O)(=O)N34CCN5CCN6CCN(CC3)[Cu]654)C=CC=C12.CNC1=NN2=C(C)C(C)=N3/C=C(/NC)N(C)[Cu]32S1.C[C@@H]1C(CO)O[C@@H](N23CCN4CCN5CCN(CC2)[Cu]543)C(O)[C@H]1O GAICUQHMMOBKJK-DWVKLTIVSA-M 0.000 description 2
- PCLJUKXNMLVKEB-AWPHKDASSA-L C1C[SH]2CC[SH]3CC[SH]4CCN1[Cu]243.CN/C1=N/N2=C(C)C=N3NC(NC)S[Cu]32N1C.CN12CCCN3CCN4CCCN(CC1)[Cu]432.CNC1=NN2=C(C)C=N3/N=C(/NC)N(C)[Cu]32S1.OCC1O[C@@H](N23CCN4CCN5([C@@H]6OC(CO)[C@@H](O)[C@H](O)C6O)CCN(CC2)[Cu]435)C(O)[C@@H](O)[C@@H]1O.[Cu].[H]O/N=C(\C)[C@@H](C)NCC(C)(C)CN[C@H](C)/C(C)=N/O Chemical compound C1C[SH]2CC[SH]3CC[SH]4CCN1[Cu]243.CN/C1=N/N2=C(C)C=N3NC(NC)S[Cu]32N1C.CN12CCCN3CCN4CCCN(CC1)[Cu]432.CNC1=NN2=C(C)C=N3/N=C(/NC)N(C)[Cu]32S1.OCC1O[C@@H](N23CCN4CCN5([C@@H]6OC(CO)[C@@H](O)[C@H](O)C6O)CCN(CC2)[Cu]435)C(O)[C@@H](O)[C@@H]1O.[Cu].[H]O/N=C(\C)[C@@H](C)NCC(C)(C)CN[C@H](C)/C(C)=N/O PCLJUKXNMLVKEB-AWPHKDASSA-L 0.000 description 2
- PRUJYKKEWAJDRI-QMVMUTFZSA-N CN(CC1=NC=CC=C1)CC1=NC=CC=C1.[64Cu] Chemical compound CN(CC1=NC=CC=C1)CC1=NC=CC=C1.[64Cu] PRUJYKKEWAJDRI-QMVMUTFZSA-N 0.000 description 2
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 2
- 206010011086 Coronary artery occlusion Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910004879 Na2S2O5 Inorganic materials 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UBAXRAHSPKWNCX-UHFFFAOYSA-N diallyl trisulfide Chemical compound C=CCSSSCC=C UBAXRAHSPKWNCX-UHFFFAOYSA-N 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- RSXLENQNWBYWOB-UHFFFAOYSA-N ethyl 3-(1,4,7,10-tetrazacyclododec-1-yl)propanoate Chemical compound N1(CCNCCNCCNCC1)CCC(=O)OCC RSXLENQNWBYWOB-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008810 intracellular oxidative stress Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- TTYFTQUHBLVXME-UHFFFAOYSA-N n,n-dimethyl-5-(1,4,7,10-tetrazacyclododec-1-ylsulfonyl)naphthalen-1-amine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N1CCNCCNCCNCC1 TTYFTQUHBLVXME-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 2
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- AAURODLQWLAQSK-RKQHYHRCSA-N (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(1,4,7,10-tetrazacyclododec-1-yl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@H]([C@@H]([C@H]([C@@H]1O)O)O)N1CCNCCNCCNCC1 AAURODLQWLAQSK-RKQHYHRCSA-N 0.000 description 1
- AAURODLQWLAQSK-RGDJUOJXSA-N (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(1,4,7,10-tetrazacyclododec-1-yl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H]([C@@H]([C@H]([C@@H]1O)O)O)N1CCNCCNCCNCC1 AAURODLQWLAQSK-RGDJUOJXSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 1
- XHCNINMOALIGKM-KBPBESRZSA-N (7s,14s)-5,5,7,12,12,14-hexamethyl-1,4,8,11-tetrazacyclotetradecane Chemical compound C[C@H]1CC(C)(C)NCCN[C@@H](C)CC(C)(C)NCCN1 XHCNINMOALIGKM-KBPBESRZSA-N 0.000 description 1
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 1
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 1
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 1
- WHIVNJATOVLWBW-PLNGDYQASA-N (nz)-n-butan-2-ylidenehydroxylamine Chemical compound CC\C(C)=N/O WHIVNJATOVLWBW-PLNGDYQASA-N 0.000 description 1
- YBBLOADPFWKNGS-UHFFFAOYSA-N 1,1-dimethylurea Chemical compound CN(C)C(N)=O YBBLOADPFWKNGS-UHFFFAOYSA-N 0.000 description 1
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 1
- LADZJJOUGVGJHM-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotridecane Chemical compound C1CNCCNCCNCCNC1 LADZJJOUGVGJHM-UHFFFAOYSA-N 0.000 description 1
- LWYYJGNZCOOFSO-UHFFFAOYSA-N 1,4,8,11-tetrazabicyclo[6.6.3]heptadecane Chemical compound C1CCNCCN2CCCNCCN1CCC2 LWYYJGNZCOOFSO-UHFFFAOYSA-N 0.000 description 1
- VQFZKDXSJZVGDA-UHFFFAOYSA-N 1,5,9-triazacyclododecane Chemical compound C1CNCCCNCCCNC1 VQFZKDXSJZVGDA-UHFFFAOYSA-N 0.000 description 1
- PWJHXHMUGFXPSN-UHFFFAOYSA-N 1,7-dioxa-4,10-diazacyclododecane Chemical compound C1COCCNCCOCCN1 PWJHXHMUGFXPSN-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- VSHOGDPTIIHVSB-UHFFFAOYSA-N 1-(chloromethyl)anthracene Chemical compound C1=CC=C2C=C3C(CCl)=CC=CC3=CC2=C1 VSHOGDPTIIHVSB-UHFFFAOYSA-N 0.000 description 1
- GWXSMIOWBINEFF-UHFFFAOYSA-N 1-methyl-1,4,8,11-tetrazacyclotetradecane Chemical compound CN1CCCNCCNCCCNCC1 GWXSMIOWBINEFF-UHFFFAOYSA-N 0.000 description 1
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- YXGRPRJSZBLDJA-UHFFFAOYSA-N 2,5,5,7,9,12,12,14-octamethyl-1,4,8,11-tetrazacyclotetradecane Chemical compound CC1CNC(C)(C)CC(C)NC(C)CNC(C)(C)CC(C)N1 YXGRPRJSZBLDJA-UHFFFAOYSA-N 0.000 description 1
- KSJBMDCFYZKAFH-UHFFFAOYSA-N 2-(2-sulfanylethylsulfanyl)ethanethiol Chemical compound SCCSCCS KSJBMDCFYZKAFH-UHFFFAOYSA-N 0.000 description 1
- OKWOSNVPILWYNU-UHFFFAOYSA-N 2-[(4-nitrophenyl)methyl]-1,4,7,10-tetrazacyclododecane Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC1NCCNCCNCCNC1 OKWOSNVPILWYNU-UHFFFAOYSA-N 0.000 description 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 1
- WCBHWWCRMPMBTH-UHFFFAOYSA-N 4-[[4-(1,4,7,10-tetrazacyclotridec-4-ylmethyl)phenyl]methyl]-1,4,7,10-tetrazacyclotridecane Chemical compound C=1C=C(CN2CCNCCNCCCNCC2)C=CC=1CN1CCNCCCNCCNCC1 WCBHWWCRMPMBTH-UHFFFAOYSA-N 0.000 description 1
- HZYLVYNCWLAIGF-UHFFFAOYSA-N 4-[[[2-(cyclohexylamino)-2-oxoethyl]-(4-propan-2-ylbenzoyl)amino]methyl]-N-hydroxybenzamide Chemical compound CC(C)c1ccc(cc1)C(=O)N(CC(=O)NC1CCCCC1)Cc1ccc(cc1)C(=O)NO HZYLVYNCWLAIGF-UHFFFAOYSA-N 0.000 description 1
- MWVKLRSIDOXBSE-UHFFFAOYSA-N 5-(1-piperidin-4-ylpyrazol-4-yl)-3-(6-pyrrolidin-1-yl-1,3-benzoxazol-2-yl)pyridin-2-amine Chemical compound NC1=NC=C(C2=CN(N=C2)C2CCNCC2)C=C1C(OC1=C2)=NC1=CC=C2N1CCCC1 MWVKLRSIDOXBSE-UHFFFAOYSA-N 0.000 description 1
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 1
- VCUKKMIXURRDKL-UHFFFAOYSA-N 9-(dimethylamino)-3-(4-ethylphenyl)pyrido[1,2]thieno[3,4-d]pyrimidin-4-one Chemical compound C1=CC(CC)=CC=C1N1C(=O)C(SC=2C3=C(N(C)C)C=CN=2)=C3N=C1 VCUKKMIXURRDKL-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 1
- VTBCYXWAEXQEST-LDAMREJGSA-N C1=CC(CN23CCN4CCCN5CCN(CC2)[64Cu]543)=CC=C1CN12CCN3CCCN4CCN(CC1)[64Cu]432 Chemical compound C1=CC(CN23CCN4CCCN5CCN(CC2)[64Cu]543)=CC=C1CN12CCN3CCCN4CCN(CC1)[64Cu]432 VTBCYXWAEXQEST-LDAMREJGSA-N 0.000 description 1
- JBWKTBBIQLRHAX-QMVMUTFZSA-N C1=CC2=CC3=C(C=CC=C3)C(CN34CCN5(CC6=C7C=CC=CC7=CC7=C6C=CC=C7)CCN6(CC7=C8C=CC=CC8=CC8=C7C=CC=C8)CCN(CC7=C8C=CC=CC8=CC8=C7C=CC=C8)(CC3)[64Cu]456)=C2C=C1 Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN34CCN5(CC6=C7C=CC=CC7=CC7=C6C=CC=C7)CCN6(CC7=C8C=CC=CC8=CC8=C7C=CC=C8)CCN(CC7=C8C=CC=CC8=CC8=C7C=CC=C8)(CC3)[64Cu]456)=C2C=C1 JBWKTBBIQLRHAX-QMVMUTFZSA-N 0.000 description 1
- SRUUTPFSLDJDJN-QMVMUTFZSA-N C1=CC2=CC3=C(C=CC=C3)C(CN34CCN5CCN6CCN(CC3)[64Cu]654)=C2C=C1 Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN34CCN5CCN6CCN(CC3)[64Cu]654)=C2C=C1 SRUUTPFSLDJDJN-QMVMUTFZSA-N 0.000 description 1
- HOACTJZIALIQBA-UHFFFAOYSA-N C1=CC2=CC3=C(C=CC=C3)C(CN3CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CC3)=C2C=C1.C1=CC=C(CN(CCN(CC2=CC=CC=N2)CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.C1=CN=C(CCCC2=NC=CC=C2)C=C1.C1CNCCN2CCCNCCN(C1)CCC2.CCN1CCN(CC)CCN(CC)CC1.[Cu].[Cu].[Cu].[Cu] Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN3CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CC3)=C2C=C1.C1=CC=C(CN(CCN(CC2=CC=CC=N2)CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.C1=CN=C(CCCC2=NC=CC=C2)C=C1.C1CNCCN2CCCNCCN(C1)CCC2.CCN1CCN(CC)CCN(CC)CC1.[Cu].[Cu].[Cu].[Cu] HOACTJZIALIQBA-UHFFFAOYSA-N 0.000 description 1
- RGENMTOCEGSRIR-UHFFFAOYSA-N C1=CC2=CC3=C(C=CC=C3)C(CN3CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CC3)=C2C=C1.C1CNCCNCCN1.CC#N.ClCC1=C2/C=C\C=C/C2=CC2=C1C=CC=C2 Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN3CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CC3)=C2C=C1.C1CNCCNCCN1.CC#N.ClCC1=C2/C=C\C=C/C2=CC2=C1C=CC=C2 RGENMTOCEGSRIR-UHFFFAOYSA-N 0.000 description 1
- ATXKWAODCWGODM-QMVMUTFZSA-N C1=CC2=CC3=C(C=CC=C3)C(CN3CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CC3)=C2C=C1.[64Cu] Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN3CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CC3)=C2C=C1.[64Cu] ATXKWAODCWGODM-QMVMUTFZSA-N 0.000 description 1
- ZWBBPDVQOYVZRS-UHFFFAOYSA-N C1=CC2=CC3=C(C=CC=C3)C(CN3CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CC3)=C2C=C1.C1CNCCNCCNCCN1.ClCC1=C2/C=C\C=C/C2=CC2=C1C=CC=C2 Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN3CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CCN(CC4=C5C=CC=CC5=CC5=C4C=CC=C5)CC3)=C2C=C1.C1CNCCNCCNCCN1.ClCC1=C2/C=C\C=C/C2=CC2=C1C=CC=C2 ZWBBPDVQOYVZRS-UHFFFAOYSA-N 0.000 description 1
- OGXMQDLSHMBJMQ-UHFFFAOYSA-N C1=CC2=CC3=C(C=CC=C3)C(CN3CCNCCNCC3)=C2C=C1.C1CN2CCCN3CCCN(C1)[Cu]23.C1CN2CCN3CCN1[Cu]23.CCN1CCNCCNCC1.CN(C)C1=CC=CC2=C(S(=O)(=O)N34CCN5CCN(CC3)[Cu]54)C=CC=C12.CN1CCN(C)CCN(C)CC1.CN1CCNCCNCC1.[Cu].[Cu].[Cu].[Cu] Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN3CCNCCNCC3)=C2C=C1.C1CN2CCCN3CCCN(C1)[Cu]23.C1CN2CCN3CCN1[Cu]23.CCN1CCNCCNCC1.CN(C)C1=CC=CC2=C(S(=O)(=O)N34CCN5CCN(CC3)[Cu]54)C=CC=C12.CN1CCN(C)CCN(C)CC1.CN1CCNCCNCC1.[Cu].[Cu].[Cu].[Cu] OGXMQDLSHMBJMQ-UHFFFAOYSA-N 0.000 description 1
- NQDOBDXIVRPYLZ-UHFFFAOYSA-N C1=CC2=CC3=C(C=CC=C3)C(CN3CCNCCNCC3)=C2C=C1.C1CNCCNCCN1.CC#N.ClCC1=C2/C=C\C=C/C2=CC2=C1C=CC=C2 Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN3CCNCCNCC3)=C2C=C1.C1CNCCNCCN1.CC#N.ClCC1=C2/C=C\C=C/C2=CC2=C1C=CC=C2 NQDOBDXIVRPYLZ-UHFFFAOYSA-N 0.000 description 1
- CNEVNJWPMJZMOP-QMVMUTFZSA-N C1=CC2=CC3=C(C=CC=C3)C(CN3CCNCCNCC3)=C2C=C1.[64Cu] Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN3CCNCCNCC3)=C2C=C1.[64Cu] CNEVNJWPMJZMOP-QMVMUTFZSA-N 0.000 description 1
- QLRASFFEYOIJHO-UHFFFAOYSA-N C1=CC2=CC3=C(C=CC=C3)C(CN3CCNCCNCCNCC3)=C2C=C1.C1CNCCNCCNCCN1.ClCC1=C2/C=C\C=C/C2=CC2=C1C=CC=C2 Chemical compound C1=CC2=CC3=C(C=CC=C3)C(CN3CCNCCNCCNCC3)=C2C=C1.C1CNCCNCCNCCN1.ClCC1=C2/C=C\C=C/C2=CC2=C1C=CC=C2 QLRASFFEYOIJHO-UHFFFAOYSA-N 0.000 description 1
- OTSMQRJMYDAFLV-QMVMUTFZSA-N C1=CC=C(CN(CCN(CC2=CC=CC=N2)CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.[64Cu] Chemical compound C1=CC=C(CN(CCN(CC2=CC=CC=N2)CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.[64Cu] OTSMQRJMYDAFLV-QMVMUTFZSA-N 0.000 description 1
- OWSJMZRAQIRRCB-QMVMUTFZSA-N C1=CN=C(CCCC2=NC=CC=C2)C=C1.[64Cu] Chemical compound C1=CN=C(CCCC2=NC=CC=C2)C=C1.[64Cu] OWSJMZRAQIRRCB-QMVMUTFZSA-N 0.000 description 1
- VUZSIWWGAFXGHI-QMVMUTFZSA-N C1CN2CCCN3CCCN(C1)[64Cu]23 Chemical compound C1CN2CCCN3CCCN(C1)[64Cu]23 VUZSIWWGAFXGHI-QMVMUTFZSA-N 0.000 description 1
- XPVUWNNWLZFNKK-QMVMUTFZSA-N C1CN2CCN3CCCN4CCN(C1)[64Cu]234 Chemical compound C1CN2CCN3CCCN4CCN(C1)[64Cu]234 XPVUWNNWLZFNKK-QMVMUTFZSA-N 0.000 description 1
- OBOSOBZYMIYQRL-QMVMUTFZSA-N C1CN2CCN3CCN1[64Cu]23 Chemical compound C1CN2CCN3CCN1[64Cu]23 OBOSOBZYMIYQRL-QMVMUTFZSA-N 0.000 description 1
- HVDCJXLLANZLEK-QMVMUTFZSA-N C1CN2CCN3CCN4CCN(C1)[64Cu]234 Chemical compound C1CN2CCN3CCN4CCN(C1)[64Cu]234 HVDCJXLLANZLEK-QMVMUTFZSA-N 0.000 description 1
- ORIZJGYQQNWBKV-QMVMUTFZSA-N C1CN2CCN3CCN4CCN1[64Cu]243 Chemical compound C1CN2CCN3CCN4CCN1[64Cu]243 ORIZJGYQQNWBKV-QMVMUTFZSA-N 0.000 description 1
- WEONZNWZBKZKTF-QMVMUTFZSA-N C1CNCCN2CCCN(C1)CCNCC2.[64Cu] Chemical compound C1CNCCN2CCCN(C1)CCNCC2.[64Cu] WEONZNWZBKZKTF-QMVMUTFZSA-N 0.000 description 1
- QDXJFWXPBMKBNI-OUMJLSBWSA-N C1CNCCN2CCCNCCN(C1)CCC2.CN(CC1=NC=CC=C1)CC1=NC=CC=C1.[64Cu] Chemical compound C1CNCCN2CCCNCCN(C1)CCC2.CN(CC1=NC=CC=C1)CC1=NC=CC=C1.[64Cu] QDXJFWXPBMKBNI-OUMJLSBWSA-N 0.000 description 1
- QAIZLBJGUJEZEA-QMVMUTFZSA-N C1CNCCN2CCCNCCN(C1)CCC2.[64Cu] Chemical compound C1CNCCN2CCCNCCN(C1)CCC2.[64Cu] QAIZLBJGUJEZEA-QMVMUTFZSA-N 0.000 description 1
- AUXKBPVJMRQAAW-UHFFFAOYSA-N C1CNCCNCCN1.CC#N.CCBr.CCN1CCN(CC)CCN(CC)CC1 Chemical compound C1CNCCNCCN1.CC#N.CCBr.CCN1CCN(CC)CCN(CC)CC1 AUXKBPVJMRQAAW-UHFFFAOYSA-N 0.000 description 1
- OLGYAFGOOSQNOV-UHFFFAOYSA-N C1CNCCNCCN1.CC#N.CCBr.CCN1CCNCCNCC1 Chemical compound C1CNCCNCCN1.CC#N.CCBr.CCN1CCNCCNCC1 OLGYAFGOOSQNOV-UHFFFAOYSA-N 0.000 description 1
- UQMUZHQCZRIPKR-UHFFFAOYSA-N C1CNCCNCCN1.CC#N.CN1CCN(C)CCN(C)CC1 Chemical compound C1CNCCNCCN1.CC#N.CN1CCN(C)CCN(C)CC1 UQMUZHQCZRIPKR-UHFFFAOYSA-N 0.000 description 1
- PLOABPOHHCOEHC-UHFFFAOYSA-N C1CNCCNCCN1.CI.CN1CCNCCNCC1 Chemical compound C1CNCCNCCN1.CI.CN1CCNCCNCC1 PLOABPOHHCOEHC-UHFFFAOYSA-N 0.000 description 1
- PZIAWWIRSGHEQQ-UHFFFAOYSA-N C1CNCCNCCNCCN1.CCOC(=O)CCBr.CCOC(=O)CCN1CCNCCNCCNCC1 Chemical compound C1CNCCNCCNCCN1.CCOC(=O)CCBr.CCOC(=O)CCN1CCNCCNCCNCC1 PZIAWWIRSGHEQQ-UHFFFAOYSA-N 0.000 description 1
- OZOGIZVZMFMJOH-UHFFFAOYSA-N C1CNCCNCCNCCN1.CN(C)C1=CC=CC2=C(S(=O)(=O)N3CCNCCNCCNCC3)C=CC=C12.ClCC1=C2/C=C\C=C/C2=CC2=C1C=CC=C2 Chemical compound C1CNCCNCCNCCN1.CN(C)C1=CC=CC2=C(S(=O)(=O)N3CCNCCNCCNCC3)C=CC=C12.ClCC1=C2/C=C\C=C/C2=CC2=C1C=CC=C2 OZOGIZVZMFMJOH-UHFFFAOYSA-N 0.000 description 1
- OXCVLJDGBLNFGY-KAMQTFOJSA-N C1CNCCNCCNCCN1.OCC1OC(O)C(O)[C@@H](O)[C@@H]1O.OCC1O[C@@H](N2CCNCCNCCNCC2)C(O)[C@@H](O)[C@@H]1O Chemical compound C1CNCCNCCNCCN1.OCC1OC(O)C(O)[C@@H](O)[C@@H]1O.OCC1O[C@@H](N2CCNCCNCCNCC2)C(O)[C@@H](O)[C@@H]1O OXCVLJDGBLNFGY-KAMQTFOJSA-N 0.000 description 1
- RFPLFZZSPHFULP-QMVMUTFZSA-N C1CO2CCN3CCO4CCN1[64Cu]324 Chemical compound C1CO2CCN3CCO4CCN1[64Cu]324 RFPLFZZSPHFULP-QMVMUTFZSA-N 0.000 description 1
- VGYHQRCPPFYRCJ-UHFFFAOYSA-N C1CSCCSCCSCCN1.CC(C)(C)OC(=O)N(CCCl)CCCl.CC(C)(C)OC(=O)N1CCSCCSCCSCC1.SCCSCCS Chemical compound C1CSCCSCCSCCN1.CC(C)(C)OC(=O)N(CCCl)CCCl.CC(C)(C)OC(=O)N1CCSCCSCCSCC1.SCCSCCS VGYHQRCPPFYRCJ-UHFFFAOYSA-N 0.000 description 1
- RTJMJMSXGDKAMU-QMVMUTFZSA-N C1C[SH]2CC[SH]3CC[SH]4CCN1[64Cu]243 Chemical compound C1C[SH]2CC[SH]3CC[SH]4CCN1[64Cu]243 RTJMJMSXGDKAMU-QMVMUTFZSA-N 0.000 description 1
- DGJMHKMYSDYOFP-MRXNPFEDSA-N C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O Chemical compound C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O DGJMHKMYSDYOFP-MRXNPFEDSA-N 0.000 description 1
- YAQVVYURAHHOAL-YJUPVLRWSA-N CC(=O)C(C)=O.CN/C(S)=N/N=C(C)/C(C)=N/N.CNC(=N/N=C(C)/C(C)=N/N=C(\S)NC)NC.CNC(=S)N/N=C(\C)C(C)=O.CNC(=S)NN.CNC(C)=O Chemical compound CC(=O)C(C)=O.CN/C(S)=N/N=C(C)/C(C)=N/N.CNC(=N/N=C(C)/C(C)=N/N=C(\S)NC)NC.CNC(=S)N/N=C(\C)C(C)=O.CNC(=S)NN.CNC(C)=O YAQVVYURAHHOAL-YJUPVLRWSA-N 0.000 description 1
- XECBJNATBZDSIV-QMVMUTFZSA-N CC1=CC=CC2=C(S(=O)(=O)N34CCN5CCN6CCN(CC3)[64Cu]654)C=CC=C12 Chemical compound CC1=CC=CC2=C(S(=O)(=O)N34CCN5CCN6CCN(CC3)[64Cu]654)C=CC=C12 XECBJNATBZDSIV-QMVMUTFZSA-N 0.000 description 1
- YNZFDMRAJWZOMM-FJLUIJIKSA-N CC1=N2C(C)CN3C(C)(C)C/C(C)=N4/C(C)CN(C(C)(C)C1)[64Cu]324 Chemical compound CC1=N2C(C)CN3C(C)(C)C/C(C)=N4/C(C)CN(C(C)(C)C1)[64Cu]324 YNZFDMRAJWZOMM-FJLUIJIKSA-N 0.000 description 1
- GKLKHWQCVKFGBN-QMVMUTFZSA-N CC1CCN2C3CCCCC3N3C(C)CCN4C5CCCCC5N1[64Cu]423 Chemical compound CC1CCN2C3CCCCC3N3C(C)CCN4C5CCCCC5N1[64Cu]423 GKLKHWQCVKFGBN-QMVMUTFZSA-N 0.000 description 1
- VLZBPLWFDJRBET-QMVMUTFZSA-N CC1CN2C(C)(C)CC(C)N3C(C)CN4C(C)(C)CC(C)N1[64Cu]342 Chemical compound CC1CN2C(C)(C)CC(C)N3C(C)CN4C(C)(C)CC(C)N1[64Cu]342 VLZBPLWFDJRBET-QMVMUTFZSA-N 0.000 description 1
- NLLSFURTSYCLIW-LLMPGSTISA-N CC1CN2C(C)(C)C[C@H](C)N3CCN4C(C)(C)C[C@H](C)N1[64Cu]324 Chemical compound CC1CN2C(C)(C)C[C@H](C)N3CCN4C(C)(C)C[C@H](C)N1[64Cu]324 NLLSFURTSYCLIW-LLMPGSTISA-N 0.000 description 1
- CQSZEPSPVBCPSN-JFMUQQRKSA-N CC1\N=C(\CC(NCC(/N=C(/CC(NC1)(C)C)\C)C)(C)C)/C Chemical compound CC1\N=C(\CC(NCC(/N=C(/CC(NC1)(C)C)\C)C)(C)C)/C CQSZEPSPVBCPSN-JFMUQQRKSA-N 0.000 description 1
- FUHSVPBAKYAVGL-QMVMUTFZSA-N CCN1CCN(CC)CCN(CC)CC1.[64Cu] Chemical compound CCN1CCN(CC)CCN(CC)CC1.[64Cu] FUHSVPBAKYAVGL-QMVMUTFZSA-N 0.000 description 1
- IZZHGALDMMNBNT-QMVMUTFZSA-N CCN1CCNCCNCC1.[64Cu] Chemical compound CCN1CCNCCNCC1.[64Cu] IZZHGALDMMNBNT-QMVMUTFZSA-N 0.000 description 1
- FEIABAGOOMIWLK-QMVMUTFZSA-N CCOC(=O)CCN12CCN3CCN4CCN(CC1)[64Cu]432 Chemical compound CCOC(=O)CCN12CCN3CCN4CCN(CC1)[64Cu]432 FEIABAGOOMIWLK-QMVMUTFZSA-N 0.000 description 1
- JCVQIVRIJOEEDW-QMVMUTFZSA-N CN(C)C1=CC=CC2=C(S(=O)(=O)N34CCN5CCN(CC3)[64Cu]54)C=CC=C12 Chemical compound CN(C)C1=CC=CC2=C(S(=O)(=O)N34CCN5CCN(CC3)[64Cu]54)C=CC=C12 JCVQIVRIJOEEDW-QMVMUTFZSA-N 0.000 description 1
- KVIJODJIULBSNM-QMVMUTFZSA-N CN12CCN3CCCN4CCN(CC1)[64Cu]432 Chemical compound CN12CCN3CCCN4CCN(CC1)[64Cu]432 KVIJODJIULBSNM-QMVMUTFZSA-N 0.000 description 1
- IPUXUXNBAXQOAL-QMVMUTFZSA-N CN1CCN(C)CCN(C)CC1.[64Cu] Chemical compound CN1CCN(C)CCN(C)CC1.[64Cu] IPUXUXNBAXQOAL-QMVMUTFZSA-N 0.000 description 1
- JMZNXQLDTBDOHT-QMVMUTFZSA-N CN1CCNCCNCC1.[64Cu] Chemical compound CN1CCNCCNCC1.[64Cu] JMZNXQLDTBDOHT-QMVMUTFZSA-N 0.000 description 1
- WJLCAVDJNMNNFK-QMVMUTFZSA-M CNC1=N/N2=C(C)/C(C)=N3/N=C(/NC)S[64Cu]23N1C Chemical compound CNC1=N/N2=C(C)/C(C)=N3/N=C(/NC)S[64Cu]23N1C WJLCAVDJNMNNFK-QMVMUTFZSA-M 0.000 description 1
- WYDQUDCHZNYZKM-QMVMUTFZSA-M CNC1=N/N2=C(C)/C=N3/N=C(/NC)S[64Cu]32N1C Chemical compound CNC1=N/N2=C(C)/C=N3/N=C(/NC)S[64Cu]32N1C WYDQUDCHZNYZKM-QMVMUTFZSA-M 0.000 description 1
- NMZMXZDVTYPIMA-QMVMUTFZSA-M CNC1=N/N2=C/C(C)=N3/N=C(/NC)S[64Cu]23N1C Chemical compound CNC1=N/N2=C/C(C)=N3/N=C(/NC)S[64Cu]23N1C NMZMXZDVTYPIMA-QMVMUTFZSA-M 0.000 description 1
- ZQXFPFKRNPWOCZ-MCVXHIJGSA-N C[C@H]1CC(C)(C)N2CCN3[C@H](C)CC(C)(C)N4CCN1[64Cu]324 Chemical compound C[C@H]1CC(C)(C)N2CCN3[C@H](C)CC(C)(C)N4CCN1[64Cu]324 ZQXFPFKRNPWOCZ-MCVXHIJGSA-N 0.000 description 1
- 101100172879 Caenorhabditis elegans sec-5 gene Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010010737 Ceruletide Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 1
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000016924 KATP Channels Human genes 0.000 description 1
- 108010053914 KATP Channels Proteins 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- DPWRJWOZCKYBEL-UHFFFAOYSA-N N,N-dimethyl-5-(1,4,7-triazonan-1-ylsulfonyl)naphthalen-1-amine Chemical compound N1(CCNCCNCC1)S(=O)(=O)C1=C2C=CC=C(C2=CC=C1)N(C)C DPWRJWOZCKYBEL-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- UOJUQZGTFQKROZ-QMVMUTFZSA-N O=[N+]([O-])C1=CC=C(CC2CN3CCN4CCN5CCN2[64Cu]453)C=C1 Chemical compound O=[N+]([O-])C1=CC=C(CC2CN3CCN4CCN5CCN2[64Cu]453)C=C1 UOJUQZGTFQKROZ-QMVMUTFZSA-N 0.000 description 1
- HEOMSVHHLZAQPQ-ZNSPFILFSA-N OCC1O[C@@H](N23CCN4CCN5([C@@H]6OC(CO)[C@@H](O)[C@H](O)C6O)CCN(CC2)[64Cu]435)C(O)[C@@H](O)[C@@H]1O Chemical compound OCC1O[C@@H](N23CCN4CCN5([C@@H]6OC(CO)[C@@H](O)[C@H](O)C6O)CCN(CC2)[64Cu]435)C(O)[C@@H](O)[C@@H]1O HEOMSVHHLZAQPQ-ZNSPFILFSA-N 0.000 description 1
- LKYPODVGYAPUBM-PJJQXMOHSA-N OCC1O[C@@H](N23CCN4CCN5CCN(CC2)[64Cu]543)C(O)[C@@H](O)[C@@H]1O Chemical compound OCC1O[C@@H](N23CCN4CCN5CCN(CC2)[64Cu]543)C(O)[C@@H](O)[C@@H]1O LKYPODVGYAPUBM-PJJQXMOHSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- BEXZJJQVPWJPOA-VOTSOKGWSA-N [(e)-hept-2-enyl] 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxylate Chemical compound CCCC\C=C\COC(=O)C1=C(C)NC(=O)NC1C1=CC=C([N+]([O-])=O)C=C1 BEXZJJQVPWJPOA-VOTSOKGWSA-N 0.000 description 1
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 1
- ZCXUVYAZINUVJD-GLCXRVCCSA-N [18F]fluorodeoxyglucose Chemical compound OC[C@H]1OC(O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-GLCXRVCCSA-N 0.000 description 1
- AFUAYXQMHSFGJC-WUZGXURASA-N [64Cu].[H]O/N=C(\C)[C@@H](C)NCC(C)(C)CN[C@H](C)/C(C)=N/O Chemical compound [64Cu].[H]O/N=C(\C)[C@@H](C)NCC(C)(C)CN[C@H](C)/C(C)=N/O AFUAYXQMHSFGJC-WUZGXURASA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 229930190815 caerulein Natural products 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 description 1
- 229960001706 ceruletide Drugs 0.000 description 1
- 159000000006 cesium salts Chemical class 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 150000004699 copper complex Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000014541 detection of hypoxia Effects 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical compound CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000002672 stereotactic surgery Methods 0.000 description 1
- YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- FQZLNQAUUMSUHT-UHFFFAOYSA-N tert-butyl n,n-bis(2-chloroethyl)carbamate Chemical compound CC(C)(C)OC(=O)N(CCCl)CCCl FQZLNQAUUMSUHT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B9/00—Instruments for examination by percussion; Pleximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic System
- C07F1/08—Copper compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
Definitions
- the present disclosure relates to a probe for detecting in vivo hydrogen sulfide, and specifically, to a probe for detecting hydrogen sulfide including a complex compound into which a radioactive isotope Cu is introduced.
- H 2 S hydrogen sulfide
- a level of hydrogen sulfide in blood plasma is known to be about 50 ⁇ M-100 ⁇ M, and results of recent studies reported that hydrogen sulfide acts as an important signaling molecule in many different physiological actions such as various inflammatory responses, cardiovascular diseases, vasodilation, glucose metabolism, neovascularization, etc., indicating that it is possible to diagnose a disease such as Down syndrome, Alzheimer's disease, diabetes, liver cirrhosis, etc. simply by detecting the level of hydrogen sulfide.
- WO 2014027820 A1 discloses a real-time biosignal measurement apparatus for cardiac ischemia and reperfusion, including a hydrogen sulfide sensor which detects hydrogen sulfide concentrations in real time.
- hydrogen sulfide is produced by three enzymes of cystathionine-synthase (CBS), cystathionine-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST), and hydrogen sulfide inhibits intracellular oxidative stress by inducing glutathione (GSH) which functions to protect cells by a cell immune system and an antioxidant action.
- CBS cystathionine-synthase
- CSE cystathionine-lyase
- 3-MST 3-mercaptopyruvate sulfurtransferase
- a method of detecting hydrogen sulfide by using a chromophore that utilizes chemical properties of intracellular cytosolic hydrogen sulfide and blood plasma hydrogen sulfide a method of detecting hydrogen sulfide by passing a specific electrode through sulfide ions, and a method of detecting hydrogen sulfide by gas chromatography have been used until now.
- various fluorescent probes have been developed. However, due to limitations of the fluorescent probe method, detection of hydrogen sulfide through imaging is very limited to a small animal level, and its application in practical bioimaging and studies on life phenomena is extremely restricted.
- an aminofluorescein compound (DPA-4-AF) having 2,2-dipicolylamine containing divalent copper ions (Cu 2+ ) was disclosed (Myung Gil Choi, et. al., Chem. Commun., (47), 7390-7392, 2009).
- An object to be achieved in the present disclosure is to provide a radioactive probe capable of selectively detecting in vivo/ex vivo hydrogen sulfide.
- the probe for detecting hydrogen sulfide according to the present disclosure may selectively bind with hydrogen sulfide to provide images of a site where hydrogen sulfide has abnormally increased in a cell or a tissue, thereby detecting a disease in an unexpected site without affecting the anatomical properties of the body.
- the probe for detecting hydrogen sulfide quickly reacts with hydrogen sulfide, thereby solving the existing problem of waiting a predetermined time for testing after an imaging agent is injected. Accordingly, the probe may be effectively used as a means for diagnosing diseases, such as a composition for imaging, an imaging method, etc.
- FIG. 1 shows a graph measuring hydrogen sulfide sensitivity of 64 Cu-labeled complex compounds according to a specific embodiment of the present disclosure
- FIGS. 2A and 2B show results of measuring radio-TLC of 64 Cu-labeled complex compounds according to a specific embodiment of the present disclosure
- FIG. 3 shows a graph measuring hydrogen sulfide reactivity of 64 Cu-labeled complex compounds according to the present disclosure over time
- FIG. 4 shows photographs of examining selective imaging through optical imaging after injecting the backs of rats with 64 Cu-labeled complex compounds according to the present disclosure
- FIGS. 5A to 5D show results of imaging paw inflammation models injected with a 64 Cu-labeled complex compound of Example 1 according to a specific embodiment of the present disclosure
- FIGS. 6A to 6C show results of imaging paw inflammation models injected with a 64 Cu-labeled complex compound of Example 20 according to a specific embodiment of the present disclosure
- FIGS. 7A to 7D show results of imaging paw inflammation models injected with 64 Cu-labeled complex compounds of Example 2 or Example 14 according to a specific embodiment of the present disclosure
- FIGS. 8A to 8E show results of imaging paw inflammation models injected with 64 Cu-labeled complex compounds of Example 3 or Example 21 according to a specific embodiment of the present disclosure
- FIGS. 9A and 9B show results of imaging paw inflammation models injected with a 64 Cu-labeled complex compound of Example 7 according to a specific embodiment of the present disclosure
- FIGS. 10A and 10B show results of imaging paw inflammation models injected with a 64 Cu-labeled complex compound of Example 9 according to a specific embodiment of the present disclosure
- FIGS. 11A to 11D show results of imaging paw inflammation models injected with a 64 Cu-labeled complex compound of Example 16 according to a specific embodiment of the present disclosure
- FIG. 12 shows the degree of inflammation in the joint regions of arthritis animal models according to a specific embodiment of the present disclosure
- FIGS. 13A and 13B show results of imaging arthritis models injected with the Cu-labeled complex compound of Example 1 according to a specific embodiment of the present disclosure
- FIG. 14 shows result of imaging brain inflammation models injected with a 64 Cu-labeled complex compound of Example 17 according to a specific embodiment of the present disclosure
- FIG. 15 shows result of imaging myocardial infarction models injected with the Cu-labeled complex compound of Example 1 according to a specific embodiment of the present disclosure
- FIG. 16 shows result of imaging myocardial infarction models injected with the Cu-labeled complex compound of Example 20 according to a specific embodiment of the present disclosure
- FIG. 17 shows result of imaging myocardial infarction models injected with the Cu-labeled complex compound of Example 16 according to a specific embodiment of the present disclosure
- FIG. 18 shows result of imaging brain tumor models injected with the 64 Cu-labeled complex compound of Example 17 according to a specific embodiment of the present disclosure
- FIGS. 19A and 19B show results of imaging tumor (EMT6) ( 19 A) and tumor (CT26) ( 19 B) injected with the 64 Cu-labeled complex compound of Example 1 according to a specific embodiment of the present disclosure, respectively;
- FIG. 20 shows result of imaging pancreatitis models injected with the 64 Cu-labeled complex compounds of Example 1 or Example 20 according to the present disclosure
- FIG. 21 shows result of imaging sepsis models injected with the 64 Cu-labeled complex compound of Example 20 according to the present disclosure
- FIG. 22 is a PET image showing a high concentration of hydrogen sulfide in the tongue of a normal rat injected with the 64 Cu-labeled complex compound of Example 1 according to the present disclosure, indicating that the 64 Cu-labeled complex compound of Example 1 according to the present disclosure is used to easily detect a site having a high concentration of in vivo hydrogen sulfide;
- FIG. 23 shows a graph quantifying decomplexation by reacting the 64 Cu-labeled complex compound of Example 20 according to the present disclosure with hydrogen sulfide at different concentrations, indicating that there is excellent correlation between the 64 Cu-labeled complex compound according to the present disclosure and hydrogen sulfide;
- FIG. 24 shows a graph of hydrogen sulfide concentrations in the plasmas of a normal rat and a myocardial infarction model rat, which were measured by using the 64 Cu-labeled complex compound of Example 20 according to the present disclosure, in which the 64 Cu-labeled complex compound of Example 20 according to the present disclosure showed measured values very similar to those of a known methylene method, and the myocardial infarction model showed a very high plasma concentration of hydrogen sulfide, as compared with the normal rat.
- the term ‘probe’ is defined as a substance which is able to detect or image an in vivo/ex vivo target.
- an imaging agent a contrast agent, a radiopharmaceutical, etc. is generally used.
- the complex compound of Chemical Formula 1 is characterized by a complex compound represented by the following Chemical Formula 5 or 6:
- the compound represented by any one of Chemical Formulae 1 to 4 is characterized by any one selected from
- the compound represented by any one of Chemical Formulae 1 to 4 is any one selected from
- the probe for detecting hydrogen sulfide according to the present disclosure may selectively bind with hydrogen sulfide and quickly reacts with hydrogen sulfide to provide images of a site where hydrogen sulfide has abnormally increased in a cell or a tissue, thereby detecting a disease in an unexpected site without affecting the anatomical properties of the body, and solving the existing problem of waiting a predetermined time for testing after an imaging agent is injected.
- the probe may be effectively used as a means for diagnosing diseases, such as a contrast agent for positron emission tomography (PET), a contrast agent for gamma camera, single photon emission computed tomography (SPECT), or Cherenkov optical imaging, a contrast agent for charge-coupled device (CCD), a contrast agent for magnetic resonance imaging (MRI), an imaging composition for computed tomography (CT), ultrasound (US), etc., or an imaging method.
- diseases such as a contrast agent for positron emission tomography (PET), a contrast agent for gamma camera, single photon emission computed tomography (SPECT), or Cherenkov optical imaging, a contrast agent for charge-coupled device (CCD), a contrast agent for magnetic resonance imaging (MRI), an imaging composition for computed tomography (CT), ultrasound (US), etc.
- PET positron emission tomography
- SPECT single photon emission computed tomography
- Cherenkov optical imaging a contrast agent for charge-coupled device
- MRI contrast
- any one complex compound of Chemical Formulae 1 to 4 is preferably included in a dose of 50 ⁇ Ci/kg-1000 ⁇ Ci/kg, based on a dose immediately before use.
- a method of imaging sulfide ions in a cell or a tissue by using the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound is disclosed.
- the imaging of sulfide ions is characterized by being performed by measuring Cherenkov radiation emitted from the radioactive isotope Cu.
- Cherenkov radiation is characterized by having a wavelength of 200 nm to 1000 nm.
- the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound is characterized by imaging sulfide ions in a site where hydrogen sulfide is abnormally increased or in a cell or extracellular matrix localized to the site, after being administered.
- a method of detecting density of hydrogen sulfide including introducing the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound into a pharmaceutical carrier; injecting the probe into a mammal excluding a human; and scanning the mammal excluding a human by using a radiation imaging device.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing inflammatory diseases including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- the inflammatory diseases are characterized by one or more selected from rheumatoid arthritis, non-rheumatoid inflammatory arthritis, Lyme disease-associated arthritis, inflammatory osteoarthritis, encephalomeningitis, osteomyelitis, inflammatory bowel disease, appendicitis, pancreatitis, sepsis, pyelitis, nephritis, and inflammatory diseases caused by bacterial infections.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing cardiac diseases including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- the cardiac diseases are characterized by one or more selected from myocardial infarction, cardiac ischemia, angina, cardiomyopathy, and endocarditis.
- a myocardial infarction site has a high concentration of hydrogen sulfide.
- the Cu-labeled complex compound according to the present disclosure was injected to the rats, and uptake in the myocardial infarction site was observed over time by imaging.
- the radioactive isotope Cu-introduced complex compound according to a specific embodiment of the present disclosure when the radioactive isotope Cu-introduced complex compound according to a specific embodiment of the present disclosure was injected, high uptake in the myocardial infarction site was confirmed such that the myocardial infarction site was clearly observed in the image, indicating that the radioactive isotope Cu-introduced complex compound may be effectively used as a pharmaceutical composition for diagnosing cardiac diseases, as compared with FDG which is a known imaging agent to visualize cardiac muscles as partially broken rings when it is injected for imaging.
- FDG is a known imaging agent to visualize cardiac muscles as partially broken rings when it is injected for imaging.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing Parkinson's disease including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing Alzheimer's disease including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing Down syndrome including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing tumors including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- the diagnosing of tumors is to diagnose hypoxia in tumors.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing sepsis including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing pains including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing arteriosclerosis including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing diabetes including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing stroke including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing liver cirrhosis including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing asthma including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- a pharmaceutically acceptable pharmaceutical composition for diagnosing Parkinson's disease including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- kits for preparing a radioactive isotope Cu-labeled drug which is a sterile non-pyrogenic sealed form of a solution, frozen, or lyophilized state, including 1 ng to 100 mg of the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound or a pharmaceutically acceptable salt thereof.
- the kit for preparing the drug is characterized by further including 0.01 mL-10 mL of a buffer solution at pH 1-9 and a concentration of 1 ⁇ M-10 ⁇ M.
- the buffer solution is characterized by acetic acid, phosphoric acid, citric acid, fumaric acid, butyric acid, succinic acid, tartaric acid, carbonic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glucaric acid, boric acid, or a sodium salt or potassium salt thereof.
- a method of early diagnosing a disease in an animal excluding a human by examining whether a hydrogen sulfide concentration is rapidly increased or decreased as compared with that of a normal state by measuring the hydrogen sulfide concentration in the blood or tissue using the radioactive isotope Cu-introduced complex compound.
- Dansyl chloride (1.0 equiv.) was dissolved in toluene (5 mL), and then cyclen (5.0 equiv.) was added thereto. The resulting solution was stirred at room temperature for 2 hours. Precipitated salts were removed, and an organic phase was separated and dried. The solid was purified by column chromatography.
- Step I 3-thia-1,5-pentanedithiol (a, 1 equiv.) in DMF and N-boc-bis(2-chloroethyl)amine (b, 1 equiv.) were slowly added and Cs 2 CO 3 (1.5 equiv.) was also added, and allowed to react for 96 hours at 65° C. to prepare N-Boc-[12]aneNS3 (c).
- the solvent was removed under vacuum, and the resulting product was dissolved in CH 2 Cl 2 and washed with water to remove cesium salts.
- the product was dried over MgSO 4 , and subjected to filtration and evaporation processes.
- the resulting product was purified by recrystallization with warm toluene to obtain a white crystal of Nboc-[12]aneNS3 (c).
- Step II N-Boc-[12]aneNS3 (c) was deprotected with a mixture of TFA and CH 2 Cl 2 (1:1) at room temperature for 15 minutes. Excess TFA and CH 2 Cl 2 were evaporated, and then water was added, and pH of the resulting product was adjusted to 14 by using Na 2 CO 3 and NaOH. Thereafter, the mixture was extracted with CH 2 Cl 2 , and dried over MgSO4, and subjected to filtration and evaporation processes to obtain a white crystal of [12]aneNS3.
- Step I Semicarbazide (1.0 equiv.) and 2,3-butadione (10 equiv.) were first mixed in MeOH (10 mL), and the resulting product was refluxed for 1 hour to obtain a compound c, which was then purified by column chromatography.
- Step II The compound c (1 equiv.) was first mixed with hydrazine hydrate (10 equiv.) in MeOH (10 mL), and then the resulting product was refluxed for 1 hour to obtain a compound d, which was then purified by column chromatography.
- Step III The compound d (1 equiv.) was first mixed with N,N-dimethyl urea (1 equiv.) in MeOH (10 mL), and then the resulting product was refluxed for 1 hour to obtain a compound f. The solvent was dried and the compound f was purified by column chromatography to obtain a pure compound f.
- Radioactive isotope-labeled compounds for Example 17 and a mixture of Example 18 and 18-1 were purified by using a C-18 Sep Pak column (washed with 10 mL of water to remove DMSO, the compound was eluted with 200 ⁇ L of EtOH six times).
- a 64 Cu complex compound represented by Chemical Formula 1b was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1c was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1d was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1e was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1f was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1g was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1 h was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1i was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1j was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1k was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1l was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1m was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1n was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1o was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1p was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1q was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1r was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1r′ was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1s was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 2a was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 2b was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 2c was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1t was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1u was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 4 was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 1w was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 2d was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 2e was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 2f was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 2g was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 2h was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 2i was obtained in the same manner as in Example 1.
- a 64 Cu complex compound represented by Chemical Formula 3b was obtained in the same manner as in Example 1.
- Example 2 cyclen- NaHS Example 1 Anthracene Example 3
- Example 23 Example 16
- Example 21 ( ⁇ M) cyclen (1:1) DODACD ATTCD cyclam TACN TACD 0 0 0 0 0 0 0 1 3 0 0 0 0 0 0 10 11 0 3 0 0 9 6.2 15 63 0 6 36.4 0 11 10 20 95 15 79 49.4 0 13.5 58 50 100 56 100 67.7 1.3 24.6 63 100 100 100 100 100 78.2 10.5 54.4 100
- radio-TLC results of using 64 Cu-labeled cyclen of Example 1 according to the present disclosure at different concentrations of sulfide ion showed that 64 Cu-labeled cyclen of Example 1 had Rf value greater than 0, but when 64 Cu-labeled cyclen of Example 1 reacts with sulfide ions to form 64 CuS, its Rf value was changed to 0, and it remained at a starting point without moving, and therefore, reaction was easily detected.
- Formation of copper sulfide 64 CuS was quantified by using a radio-TLC scanner.
- biothiol or salt solutions were prepared by dissolving the compounds in triple distilled water.
- Example 20 Example 1 Example 16 Example 3 Example 23 Example 21 64 Cu-TACN 64 Cu-cyclen 64 Cu-cyclam 64 Cu-DODACD* 64 Cu-AATTCD 64 Cu-TACD* Cys 0.8 ⁇ 0.3 0.5 ⁇ 0.1 0.7 ⁇ 0.2 0.4 0.5 9 ⁇ 3 Hcys 1.1 ⁇ 0.5 1.4 ⁇ 0.4 0.7 ⁇ 0.0 27 ⁇ 3 0.4 30 ⁇ 5 GSH 2.6 ⁇ 0.0 0.7 ⁇ 0.0 0.8 ⁇ 0.2 48 0.7 33 DTT 0.9 ⁇ 0.1 0.6 ⁇ 0.4 0.8 ⁇ 0.0 45 ⁇ 2 0.4 25 L-Asa 0.8 ⁇ 0.5 0.5 ⁇ 0.1 0.7 ⁇ 0.2 15 0.4 4 ⁇ 2 ME 0.4 ⁇ 0.0 0.5 ⁇ 0.1 0.5 0.6 16 0.5 2 ⁇ 2 NaCl 0.5 ⁇ 0.0 ⁇ 0.0 0.7 ⁇ 0.0 0.3 0.5 0.4 ⁇ 0.2 K
- concentrations of all biothiols and other competitive materials are 100 ⁇ M. Further, specific concentrations of biothiols, anions, and oxidants used in Table are as follows: [L-Cys (1 mM); L-Hcys (10 mM); GSH (10 mM); DL-dithiothretitol (DTT, 100 ⁇ M); L-ascorbic acid (L-AsA, 10 mM); 2-mercaptoethanol (2-ME, 10 mM); NaCl (10 mm); Kl (1 mM); Na 2 S 2 O 3 (1 mM); Na 2 S 2 O 5 (1 mM); NaOAc (1 mM); H 2 O 2 (100 M); NaClO 4 (100 ⁇ M); NaHCO 3 (100 ⁇ M); NaNO 2 (100 M); NaN 3 (100 ⁇ M); ATB 337 (100 ⁇ M); diallyl trisulphide (100 ⁇ M)].
- results of measuring reactivity with various anions containing sulfur showed that 64 Cu-labeled complex compounds of Examples 1, 2, 16 and 20 according to the present disclosure selectively reacted with hydrogen sulfide whereas 64 Cu-labeled complex compounds of Examples 3 and 21 did not selectively react with hydrogen sulfide, and they also reacted with other biothiol compounds or anions.
- a colon carcinoma cell CT-26 was seeded in each plate at a density of 5 ⁇ 10 6 , and then 10 ⁇ Ci-300 ⁇ Ci of 64 Cu-labeled complex compound of Examples 1, 7 or 9 according to the present disclosure was treated thereto, followed by incubation for 10 minutes.
- the cells were washed with PBS, and then 0 ⁇ M, 1 ⁇ M, or 50 ⁇ M of NaHS solution was added thereto, followed by incubation for 5 minutes. Thereafter, the cells were washed with PBS, and then cells were removed from the plate by adding trypsin and EDTA, followed by centrifugation. Supernatants were discarded and radiation of remaining cells was measured by using a gamma counter.
- Example 1 0 600 1 780 50 850
- Example 7 0 20000 1 21000 50 23000
- Example 9 0 7000 1 6500 50 6900
- Example 20 0 30000 1 32000 50 34000
- 64 Cu-labeled complex compounds according to the present disclosure showed that as the NaHS concentration was increased, radiation of 64 Cu-labeled complex compounds by cellular uptake slightly increased.
- FIG. 4 shows photographs of examining selective imaging through optical imaging after injecting the backs of rats with 64 Cu-labeled complex compounds according to the present disclosure.
- matrigel alone, matrigel+1 mg NaCl, matrigel+0.5 mg NaHS, and matrigel+0.05 mg NaHS were injected into four sites on the backs of rats, respectively.
- 1.8 mCi of the 64 Cu-labeled complex compound according to Example 1 was injected via the tails of rats, immediately followed by optical imaging.
- signals were detected only in the lower two sites injected with NaHS generating hydrogen sulfide. Even after 4 hours, signals were still detected only in the lower two sites.
- CFA complete Freund's adjuvant
- formalin was injected into only one paw (right) of the hind paws of Balb/c or ICR mice to establish inflammation models. 1 day after injection of the inflammation inducer, the mice were used in imaging or other in vivo experiments.
- a myocardial infarction model was established by using Sprague-Dawley rats (12-week-old or older, about 250 g). 2 days later after induction of myocardial infarction by occlusion of the coronary arteries in the heart, the rats were used in imaging tests. It is a known fact that myocardial infarction sites show high concentrations of hydrogen sulfide.
- An inflammation inducer, lipopolysaccharide was directly injected into one part of the brain of Sprague-Dawley rat to induce inflammation in one part of the brain. 24 hours after induction of inflammation, the rats were used in imaging tests.
- the surface of the rat's head was incised and the capillaries and meninges on the outer surface of the skull were removed. Subsequently, a hole was made at the defined coordinates by stereotactic surgery, and 20,000 C6 cells which are known as glioma cells of the rat brain were injected by using a syringe pump. After cell injection, the syringe was left for about 5 minutes to allow absorption of the cells, and then slowly removed. The hole was filled with bone cement, and then sutured to prepare a brain tumor model.
- Caerulein 50 ⁇ g/kg was intraperitoneally injected into Balb/c mouse seven times at hourly intervals to prepare a pancreatitis model.
- Nuclear medicine imaging was measured by using an Inveon PET/CT system of Siemens Healthcare, and optical imaging was measured by using IVIS spectrum CT equipment.
- Cherenkov radiation emitted from 64 Cu was measured by using a highly sensitive CCD (charge-coupled device) camera.
- Imaging was measured for 1 minute to 5 minutes, and a radiation dose was about 50 ⁇ Ci to 2000 ⁇ Ci, and photographs were variously taken as needed, such as immediately after first injection, at 1 hour, 4 hours, and 24 hours later.
- Example 1 As shown in FIG. 5D , the same results were also observed in the paw inflammation ICR and Balb/c mouse models, and 64 Cu-labeled cyclen of Example 1 according to the present disclosure showed a retention time of 24 hours or longer in the animal models, suggesting that therapeutic effects may be predicted in a non-invasive manner without continuous injection of the drug.
- 64 Cu-labeled cyclam of Example 16 showed no obvious difference in the inflamed and normal paws, and its injection showed low uptake, compared to injection of the same quantity of 64 Cu-labeled cyclen of Example 1.
- Example 1 When 64 Cu-labeled cyclen of Example 1 according to the present disclosure was injected into the arthritis model, selective uptake in the joint region was observed, as shown in FIGS. 13A and 13B .
- Inflammation was induced by injecting LPS into the half of the rat's brain, and 1 day later, 64 Cu-labeled complex compound of Example 17 according to the present disclosure was injected, followed PET imaging. As shown in FIG. 14 , higher uptake was observed in the inflamed site than in the opposite site.
- myocardial infarction sites show high concentrations of hydrogen sulfide.
- 50 ⁇ Ci-900 ⁇ Ci of the 64 Cu-labeled complex compound was injected via the tails of the rats, and uptake in the myocardial infarction site was examined over time by PET imaging.
- PET images were obtained at 72 hours after injecting the 64 Cu-labeled 1q compound of Example 17 into the prepared brain tumor rat model. High uptake was observed in the brain tumor, and this imaging study suggests that brain tumor may be diagnosed by using the probe for detecting hydrogen sulfide.
- PET images were obtained after injecting the 64 Cu-labeled complex compound of Example 1 into the prepared rat model having EMT6 tumor and rat model having CT26 tumor. Results are shown in FIGS. 19A and 19B .
- FIGS. 19A and 19B higher uptake was observed in the tumor region (red circle) than in the background, suggesting that the probe for detecting hydrogen sulfide may be used in the diagnosis of various tumors.
- the probe since EMT6 tumor is commonly used as a hypoxic tumor model, the probe may be suggested as a probe applicable to detection of hypoxia in tumors.
- Optical images were obtained after injecting each of the 64 Cu-labeled complex compounds of Example 1 and Example 20 into the prepared rat models having pancreatitis, and PET images were obtained after excision of tissues thereof. Results are shown in FIG. 20 .
- FIG. 20 high uptakes of the Cu-labeled complex compounds of Example 1 and Example 20 were observed in the pancreas (red oval) of the pancreatitis models, suggesting that the probe of the present disclosure may be used to diagnose pancreatitis.
- PET images were obtained after injecting the 64 Cu-labeled complex compound of Example 20 into the prepared rat model having sepsis. Result is shown in FIG. 21 .
- uptake was increased throughout the body of the sepsis model. In particular, increased uptake was observed in the lung, suggesting that the probe for detecting hydrogen sulfide may be used in the diagnosis of sepsis.
- PET images were obtained after injecting the 64 Cu-labeled complex compound of Example 1 into a normal rat, and PET images were obtained again after excision of the tongue thereof. Results are shown in FIG. 22 .
- PET image before excision of the tongue A
- high uptake was observed in the tongue.
- after excision B
- the uptake was decreased in the same site.
- high uptake was observed in the tongue removed by excision.
- C is a photograph taken before imaging the tongue after excision.
- Example 20 64 Cu-labeled TACN of Example 20 according to the present disclosures was reacted with various concentrations of NaHS which is a source of hydrogen sulfide, and decomplexation was measured to obtain a calibration curve, as shown in FIG. 23 . There was a very excellent correlation therebetween, suggesting that concentrations of hydrogen sulfide may be accurately determined by measuring decomplexation.
- the complex compound for detecting hydrogen sulfide according to the present disclosure may specifically detect a myocardial infarction model generating hydrogen sulfide, which is comparable to the common methylene blue method.
Abstract
Description
- This application is a Divisional of U.S. patent application Ser. No. 15/564,214, filed on Feb. 20, 2018 which is a U.S. National Stage Application of International Application No. PCT/KR2016/003559, filed on Apr. 6, 2016, which claims the benefit under 35 USC 119(a) and 365(b) of Korean Patent Application No. 10-2015-0049305, filed on Apr. 7, 2015, in the Korean Intellectual Property Office.
- The present disclosure relates to a probe for detecting in vivo hydrogen sulfide, and specifically, to a probe for detecting hydrogen sulfide including a complex compound into which a radioactive isotope Cu is introduced.
- According to results of recent studies, hydrogen sulfide (H2S) is known to be involved in various physiological phenomena as a 3rd gasotransmitter and gasomediator, together with nitric oxide and carbon monoxide.
- A level of hydrogen sulfide in blood plasma is known to be about 50 μM-100 μM, and results of recent studies reported that hydrogen sulfide acts as an important signaling molecule in many different physiological actions such as various inflammatory responses, cardiovascular diseases, vasodilation, glucose metabolism, neovascularization, etc., indicating that it is possible to diagnose a disease such as Down syndrome, Alzheimer's disease, diabetes, liver cirrhosis, etc. simply by detecting the level of hydrogen sulfide.
- Particularly, hydrogen sulfide has attracted attention because it functions as a K-ATP channel opener, and contributes to homeostasis of the cardiovascular system, and plays a role in treating cardiac muscle damage. In this regard, WO 2014027820 A1 discloses a real-time biosignal measurement apparatus for cardiac ischemia and reperfusion, including a hydrogen sulfide sensor which detects hydrogen sulfide concentrations in real time.
- Further, in vivo hydrogen sulfide is produced by three enzymes of cystathionine-synthase (CBS), cystathionine-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST), and hydrogen sulfide inhibits intracellular oxidative stress by inducing glutathione (GSH) which functions to protect cells by a cell immune system and an antioxidant action. Cytosolic hydrogen sulfide produced by CSE enters mitochondria via Katp channels under conditions of increased intracellular oxidative stress, and induces GSH, together with mitochondrial hydrogen sulfide produced by 3-MST and CAT enzymes, thereby protecting cells.
- As such, since hydrogen sulfide induces changes of the GSH concentration to actually protect cells, it serves as a mediator preventing cell dysfunction and inhibiting apoptosis. Therefore, if detection of mitochondrial hydrogen sulfide and measurement of its concentration are possible, it will contribute to studying various life phenomena.
- Accordingly, many technologies capable of detecting and quantifying hydrogen sulfide are being developed competitively, and in particular, development of a method of detecting in vivo hydrogen sulfide by non-invasive imaging has emerged as an important issue.
- Although involvement of hydrogen sulfide in disease diagnosis and physiological phenomena has received attention and various types of probes are now being introduced, detection and accurate quantification of hydrogen sulfide are known to require very difficult and complex conditions such as measurement of H2S in a liquid state, selectivity for hydrogen sulfide over other anionic species, selectivity for hydrogen sulfide over reduced glutathione (GSH), etc.
- In this regard, a method of detecting hydrogen sulfide by using a chromophore that utilizes chemical properties of intracellular cytosolic hydrogen sulfide and blood plasma hydrogen sulfide, a method of detecting hydrogen sulfide by passing a specific electrode through sulfide ions, and a method of detecting hydrogen sulfide by gas chromatography have been used until now. In recent years, various fluorescent probes have been developed. However, due to limitations of the fluorescent probe method, detection of hydrogen sulfide through imaging is very limited to a small animal level, and its application in practical bioimaging and studies on life phenomena is extremely restricted.
- As a general fluorescent probe for detecting H2S, a 2,4,6-triaryl pyridium cation compound was disclosed (Journal of the American Chemical Society, 125, 9000, 2003), but there is a problem that this compound cannot avoid competitive reaction with GSH. Further, a method of using 2,4 dinitrobenzene sulfonyl fluorescein as a fluorescence enhancement probe was suggested (Analytica Chimica Acta, 631, 91, 2009), but there is a problem that fluorescence intensity is changed over time due to hydrolysis of sulfonic acid ester.
- In addition, an aminofluorescein compound (DPA-4-AF) having 2,2-dipicolylamine containing divalent copper ions (Cu2+) was disclosed (Myung Gil Choi, et. al., Chem. Commun., (47), 7390-7392, 2009). A compound, in which a fluorescent material is attached to cyclen, cyclam, TACN, etc., is disclosed in WO2012-144654A1. This compound itself emits fluorescence, but it does not emit fluorescence by quenching of copper ions once binding with copper to form a complex compound. When hydrogen sulfide reacts with the complex compound, the copper complex is detached in a CuS form. Depending on the degree, fluorescence intensity to be restored differs. On the basis of this principle, a method of quantifying the amount of hydrogen sulfide was disclosed. However, this compound still has many problems in that images can be acquired only in vitro, and it is difficult to selectively detect hydrogen sulfide in vivo. Development of a new technology capable of replacing the known detection methods is still demanded.
- An object to be achieved in the present disclosure is to provide a radioactive probe capable of selectively detecting in vivo/ex vivo hydrogen sulfide.
- According to one representative aspect of the present disclosure, provided is a probe for detecting hydrogen sulfide (H2S), including a radioactive isotope Cu-introduced complex compound which is represented by any one of the following Chemical Formulae 1 to 4:
-
- (wherein A, B, X1 to X3, Y1, Y2, and R1 to R8 are the same as disclosed herein)
-
- (wherein K, L, M, and R15 to R17 are the same as disclosed herein)
-
- (wherein X is the same as disclosed herein)
- According to specific embodiments of the present disclosure, as a result of real-time observing animal models, in which hydrogen sulfide involved in various diseases is generated in a large quantity, through optical and nuclear medicine imaging, the probe for detecting hydrogen sulfide according to the present disclosure may selectively bind with hydrogen sulfide to provide images of a site where hydrogen sulfide has abnormally increased in a cell or a tissue, thereby detecting a disease in an unexpected site without affecting the anatomical properties of the body. In addition, the probe for detecting hydrogen sulfide quickly reacts with hydrogen sulfide, thereby solving the existing problem of waiting a predetermined time for testing after an imaging agent is injected. Accordingly, the probe may be effectively used as a means for diagnosing diseases, such as a composition for imaging, an imaging method, etc.
-
FIG. 1 shows a graph measuring hydrogen sulfide sensitivity of 64Cu-labeled complex compounds according to a specific embodiment of the present disclosure; -
FIGS. 2A and 2B show results of measuring radio-TLC of 64Cu-labeled complex compounds according to a specific embodiment of the present disclosure; -
FIG. 3 shows a graph measuring hydrogen sulfide reactivity of 64Cu-labeled complex compounds according to the present disclosure over time; -
FIG. 4 shows photographs of examining selective imaging through optical imaging after injecting the backs of rats with 64Cu-labeled complex compounds according to the present disclosure; -
FIGS. 5A to 5D show results of imaging paw inflammation models injected with a 64Cu-labeled complex compound of Example 1 according to a specific embodiment of the present disclosure; -
FIGS. 6A to 6C show results of imaging paw inflammation models injected with a 64Cu-labeled complex compound of Example 20 according to a specific embodiment of the present disclosure; -
FIGS. 7A to 7D show results of imaging paw inflammation models injected with 64Cu-labeled complex compounds of Example 2 or Example 14 according to a specific embodiment of the present disclosure; -
FIGS. 8A to 8E show results of imaging paw inflammation models injected with 64Cu-labeled complex compounds of Example 3 or Example 21 according to a specific embodiment of the present disclosure; -
FIGS. 9A and 9B show results of imaging paw inflammation models injected with a 64Cu-labeled complex compound of Example 7 according to a specific embodiment of the present disclosure; -
FIGS. 10A and 10B show results of imaging paw inflammation models injected with a 64Cu-labeled complex compound of Example 9 according to a specific embodiment of the present disclosure; -
FIGS. 11A to 11D show results of imaging paw inflammation models injected with a 64Cu-labeled complex compound of Example 16 according to a specific embodiment of the present disclosure; -
FIG. 12 shows the degree of inflammation in the joint regions of arthritis animal models according to a specific embodiment of the present disclosure; -
FIGS. 13A and 13B show results of imaging arthritis models injected with the Cu-labeled complex compound of Example 1 according to a specific embodiment of the present disclosure; -
FIG. 14 shows result of imaging brain inflammation models injected with a 64Cu-labeled complex compound of Example 17 according to a specific embodiment of the present disclosure; -
FIG. 15 shows result of imaging myocardial infarction models injected with the Cu-labeled complex compound of Example 1 according to a specific embodiment of the present disclosure; -
FIG. 16 shows result of imaging myocardial infarction models injected with the Cu-labeled complex compound of Example 20 according to a specific embodiment of the present disclosure; -
FIG. 17 shows result of imaging myocardial infarction models injected with the Cu-labeled complex compound of Example 16 according to a specific embodiment of the present disclosure; -
FIG. 18 shows result of imaging brain tumor models injected with the 64Cu-labeled complex compound of Example 17 according to a specific embodiment of the present disclosure; -
FIGS. 19A and 19B show results of imaging tumor (EMT6) (19A) and tumor (CT26) (19B) injected with the 64Cu-labeled complex compound of Example 1 according to a specific embodiment of the present disclosure, respectively; -
FIG. 20 shows result of imaging pancreatitis models injected with the 64Cu-labeled complex compounds of Example 1 or Example 20 according to the present disclosure; -
FIG. 21 shows result of imaging sepsis models injected with the 64Cu-labeled complex compound of Example 20 according to the present disclosure; -
FIG. 22 is a PET image showing a high concentration of hydrogen sulfide in the tongue of a normal rat injected with the 64Cu-labeled complex compound of Example 1 according to the present disclosure, indicating that the 64Cu-labeled complex compound of Example 1 according to the present disclosure is used to easily detect a site having a high concentration of in vivo hydrogen sulfide; -
FIG. 23 shows a graph quantifying decomplexation by reacting the 64Cu-labeled complex compound of Example 20 according to the present disclosure with hydrogen sulfide at different concentrations, indicating that there is excellent correlation between the 64Cu-labeled complex compound according to the present disclosure and hydrogen sulfide; and -
FIG. 24 shows a graph of hydrogen sulfide concentrations in the plasmas of a normal rat and a myocardial infarction model rat, which were measured by using the 64Cu-labeled complex compound of Example 20 according to the present disclosure, in which the 64Cu-labeled complex compound of Example 20 according to the present disclosure showed measured values very similar to those of a known methylene method, and the myocardial infarction model showed a very high plasma concentration of hydrogen sulfide, as compared with the normal rat. - Hereinafter, various aspects and specific embodiments of the present disclosure will be described in more detail.
- As used herein, the term ‘probe’ is defined as a substance which is able to detect or image an in vivo/ex vivo target. In place of the term, an imaging agent, a contrast agent, a radiopharmaceutical, etc. is generally used.
- According to an aspect of the present disclosure, disclosed is a probe for detecting hydrogen sulfide (H2S), including a radioactive isotope Cu-introduced complex compound which is represented by any one of the following Chemical Formulae 1 to 4:
-
- (wherein X1, X2 and X3 are each independently one or more selected from N, O, and S;
- Y1 and Y2 are each independently C or N;
- A and B are each independently one or more selected from no bond, C(R9)(R10)—C(R11)(R12)—, —C(R9)—C(R10)(R11)—C(R12)(R13)—, and C(R9)(R10)—C(R11)(R12)—C(R13)(R14)—, and ═C(R9)—C(R10)═;
- R1 to R14 are each independently one or more selected from no bond, hydrogen, hydroxy, substituted or unsubstituted C1-C6 linear or branched alkyl, substituted or unsubstituted C1-C6 linear or branched alkyloxycarbonyl, substituted or unsubstituted C5-C12 aryl C1-C6 alkyl, substituted or unsubstituted C5-C12 heterocycloalkyl, substituted or unsubstituted C5-C20 aryl, substituted or unsubstituted C5-C20 arylsulfonyl, C1-C6 alkylamine, C1-C6 dialkylamine, and substituted or unsubstituted amine,
- the ‘substituted’ means being substituted with one or more substituents selected from hydroxy, hydroxy C1-C6 alkyl, C1-C6 dialkylamine, nitro, and 64Cu-labeled 3-methyl-1,4,7,10-tetraazacyclotridecane,
- R5 and R8 or R6 and R7 bind to each other to form a C4-C8 cycloalkyl ring;
- - - - is a single bond or a double bond,
- Cu is any one selected from 60Cu, 61Cu, 62Cu, 64Cu, and 67Cu);
-
- (wherein K, L and N are each independently one or more selected from C(R18)(R19)—C(R20)(R21)—, ═C(R18)—C(R19)(R2)—C(R21)(R22)—, C(R18)(R19)—C(R20)(R21)—C(R22)(R23)—, and ═C(R18)—C(R19)—;
- R15 to R23 are each independently one or more selected from no bond, hydrogen, hydroxy, substituted or unsubstituted C1-C20 linear or branched alkyl, substituted or unsubstituted C1-C6 linear or branched alkyloxycarbonyl, substituted or unsubstituted C5-C12 aryl C1-C6 alkyl, substituted or unsubstituted C5-C12 heterocycloalkyl, substituted or unsubstituted C5-C20 aryl, substituted or unsubstituted C5-C20 arylsulfonyl, C1-C6 alkylamine, C1-C6 dialkylamine, and substituted or unsubstituted amine,
- the ‘substituted’ means being substituted with one or more substituents selected from hydroxy, hydroxy C1-C6 alkyl, C1-C6 dialkylamine, nitro, and 64Cu-labeled 3-methyl-1,4,7,10-tetraazacyclotridecane;
- Cu is any one selected from 60Cu, 61Cu, 62Cu, 64Cu, and 67Cu);
-
- (wherein X is hydrogen or a compound represented by the following
- Preferably, the complex compound of Chemical Formula 1 is characterized by a complex compound represented by the following Chemical Formula 5 or 6:
-
- (wherein A or B is one or more selected from C(R32)(R33)—C(R34)(R35)—, ═C(R32)—C(R33)(R34)—C(R35)(R36)—, and C(R32)(R33)—C(R34)(R35)—C(R36)(R37)—,
- R24 to R37 are each independently one or more selected from no bond, hydrogen, hydroxy, C1-C6 linear or branched alkyl, C1-C6 linear or branched alkyloxycarbonyl, C1-C6 linear or branched alkylamine, substituted or unsubstituted amine, C5-C12 aryl C1-C6 alkyl substituted or unsubstituted with 64Cu-labeled 3-methyl-1,4,7,10-tetraazacyclotridecane or nitro, C5-C20 heterocycloalkyl substituted or unsubstituted with hydroxy or hydroxy C1-C6 alkyl, and C5-C20 arylsulfonyl substituted or unsubstituted with C1-C6 dialkylamine,
- R26 and R27 or R30 and R31 bind to each other to form a C4-C8 cycloalkyl ring;
- Cu is any one selected from 60Cu, 61Cu, 62Cu, 64Cu, and 67Cu);
-
- (wherein A is C(R30)(R31)—C(R32)(R33)— or ═C(R30)—C(R31)═,
- R24 to R33 are each independently one or more selected from no bond, hydrogen, hydroxy, C1-C6 linear or branched alkyl, C1-C6 alkylamine, C1-C6 dialkylamine, and substituted or unsubstituted amine,
- - - - is a single bond or a double bond,
- if - - - is a double bond, R24 or R29 is no bond,
- Cu is any one selected from 60Cu, 61Cu, 62Cu, 64Cu, and 67Cu).
- More preferably, the compound represented by any one of
Chemical Formulae 1 to 4 is characterized by any one selected from -
- (1) 1,4,7,10-tetraazacyclododecane;
- (2) 1-(anthracen-9-ylmethyl)-1,4,7,10-tetraazacyclododecane;
- (3) 1,7-dioxa-4,10-diazacyclododecane;
- (4) 1,4,7,10-tetrakis(anthracen-9-ylmethyl)-1,4,7,10-tetraazacyclododecane;
- (5) (7S,14R)-5,5,7,12,12,14-hexahexamethyl-1,4,8,11-tetraazacyclotetradecane;
- (6) 2,5,5,7,9,12,12,14-octamethyl-1,4,8,11-tetraazacyclotetradecane;
- (7) (1E,7E)-2,5,5,7,9,12,12,14-octamethyl-1,4,8,11-tetraazacyclotetradeca-7,14-diene;
- (8) (7S,14S)-5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane;
- (9) 6,15-dimethyldocosahydrodibenzo[b,i][1,4,8,11]tetraazacyclotetradecene;
- (10) ethyl 3-(1,4,7,10-tetraazacyclododecan-1-yl)propanoate;
- (11) 1,4-bis((1,4,7,10-tetraazacyclotridecan-4-yl)methyl)benzene;
- (12) 2-(4-nitrobenzyl)-1,4,7,10-tetraazacyclododecane;
- (13) 1,4,7,10-tetraazacyclotridecane;
- (14) (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(1,4,7,10-tetraazacyclododecan-1-yl)tetrahydro-2H-pyran-3,4,5-triol;
- (15) 5-((1,4,7,10-tetraazacyclododecan-1-yl)sulfonyl)-N,N-dimethylnaphthalene-1-amine;
- (16) 1,4,8,11-tetraazacyclotetradecane;
- (17) (2R,2′R,3S,3'S,4S,4'S,5R,5′R,6R,6′R)-6,6′-(1,4,7,10-tetraazacyclododecane-1,7-diyl)bis(2-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-trol);
- (18) 1,4,7-triazonane;
- (19) 1,5,9-triazacyclododecane;
- (20) 5-((1,4,7-triazonan-1-yl)sulfonyl)-N,N-dimethylnaphthalene-1-amine;
- (21) 1-methyl-1,4,8,11-tetraazacyclotetradecane;
- (22) 1,4,8,11-tetraazabicyclo[6.6.3]heptadecane;
- (23) bis(pyridin-2-ylmethyl)amine;
- (24) N1,N1,N2N2-tetrakis(pyridin-2-ylmethyl)ethane-1,2-diamine;
- (25) (1Z,N′E)-N′-((E)-3-((bis(methylamino)methylene)hydrazono)butan-2-ylidene)-N-methylcarbamohydrazonothioic acid;
- (26) (1Z,N′E)-N′-((E)-2-((bis(methylamino)methylene)hydrazono)propylidene)-N-methylcarbamohydrazonothioic acid;
- (27) (2E,2′E,3R,3′R)-3-((3-(((R,E)-3-(hydroxyimino)butan-2-yl)amino)-2,2-dimethylpropyl)amino)butan-2-one oxime;
- (28) 1,4,7-trithia-10-azacyclododecane;
- (29) 1-methyl-1,4,7-triazonane;
- (30) 1-(anthracen-9-ylmethyl)-1,4,7-triazonane;
- (31) 1-hexadecyl-1,4,7-triazonane;
- (32) 1,4,7-trimethyl-1,4,7-triazonane;
- (33) 1,4,7-tris(anthracen-9-ylmethyl)-1,4,7-triazonane; and
- (34) 1,4,7-trihexadecyl-1,4,7-triazonane.
- The compound represented by any one of
Chemical Formulae 1 to 4 is any one selected from - With regard to the radioactive isotope Cu-introduced complex compound represented by any one of
Chemical Formulae 1 to 4 according to a specific embodiment of the present disclosure, as a result of real-time observing animal models, in which hydrogen sulfide involved in various diseases is generated in a large quantity, through optical and nuclear medicine imaging, the probe for detecting hydrogen sulfide according to the present disclosure may selectively bind with hydrogen sulfide and quickly reacts with hydrogen sulfide to provide images of a site where hydrogen sulfide has abnormally increased in a cell or a tissue, thereby detecting a disease in an unexpected site without affecting the anatomical properties of the body, and solving the existing problem of waiting a predetermined time for testing after an imaging agent is injected. Accordingly, the probe may be effectively used as a means for diagnosing diseases, such as a contrast agent for positron emission tomography (PET), a contrast agent for gamma camera, single photon emission computed tomography (SPECT), or Cherenkov optical imaging, a contrast agent for charge-coupled device (CCD), a contrast agent for magnetic resonance imaging (MRI), an imaging composition for computed tomography (CT), ultrasound (US), etc., or an imaging method. - In this regard, any one complex compound of
Chemical Formulae 1 to 4 is preferably included in a dose of 50 μCi/kg-1000 μCi/kg, based on a dose immediately before use. - If the dose is out of the above range, there are additional problems that a signal-to-noise ratio is too low or the radiation exposure of a patient is excessively increased.
- According to another aspect of the present disclosure, disclosed is a method of imaging sulfide ions in a cell or a tissue by using the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- In a specific embodiment of the present disclosure, the imaging of sulfide ions is characterized by being performed by measuring Cherenkov radiation emitted from the radioactive isotope Cu.
- In another specific embodiment of the present disclosure, Cherenkov radiation is characterized by having a wavelength of 200 nm to 1000 nm.
- In still another specific embodiment of the present disclosure, the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound is characterized by imaging sulfide ions in a site where hydrogen sulfide is abnormally increased or in a cell or extracellular matrix localized to the site, after being administered.
- In still another specific embodiment of the present disclosure, disclosed is a method of detecting density of hydrogen sulfide, the method including introducing the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound into a pharmaceutical carrier; injecting the probe into a mammal excluding a human; and scanning the mammal excluding a human by using a radiation imaging device.
- In still another specific embodiment of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing inflammatory diseases, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- In a specific embodiment of the present disclosure, the inflammatory diseases are characterized by one or more selected from rheumatoid arthritis, non-rheumatoid inflammatory arthritis, Lyme disease-associated arthritis, inflammatory osteoarthritis, encephalomeningitis, osteomyelitis, inflammatory bowel disease, appendicitis, pancreatitis, sepsis, pyelitis, nephritis, and inflammatory diseases caused by bacterial infections.
- In a specific embodiment of the present disclosure, as a result of conducting optical imaging and nuclear medicine imaging studies using animal models having induced paw inflammation, muscle inflammation, arthritis, or brain inflammation, selective uptake of the radioactive isotope Cu-introduced complex compound according to the present disclosure was observed in inflamed sites, and therefore, it may be effectively used as a pharmaceutical composition for diagnosing inflammatory diseases.
- In still another specific embodiment of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing cardiac diseases, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- In a specific embodiment of the present disclosure, the cardiac diseases are characterized by one or more selected from myocardial infarction, cardiac ischemia, angina, cardiomyopathy, and endocarditis.
- It is known that a myocardial infarction site has a high concentration of hydrogen sulfide. After induction of myocardial infarction by coronary artery occlusion in rats, the Cu-labeled complex compound according to the present disclosure was injected to the rats, and uptake in the myocardial infarction site was observed over time by imaging. As a result, when the radioactive isotope Cu-introduced complex compound according to a specific embodiment of the present disclosure was injected, high uptake in the myocardial infarction site was confirmed such that the myocardial infarction site was clearly observed in the image, indicating that the radioactive isotope Cu-introduced complex compound may be effectively used as a pharmaceutical composition for diagnosing cardiac diseases, as compared with FDG which is a known imaging agent to visualize cardiac muscles as partially broken rings when it is injected for imaging.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing Parkinson's disease, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing Alzheimer's disease, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing Down syndrome, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing tumors, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to a specific embodiment of the present disclosure, the diagnosing of tumors is to diagnose hypoxia in tumors.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing sepsis, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing pains, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing arteriosclerosis, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing diabetes, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing stroke, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing liver cirrhosis, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing asthma, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a pharmaceutically acceptable pharmaceutical composition for diagnosing Parkinson's disease, including the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound.
- According to still another aspect of the present disclosure, disclosed is a kit for preparing a radioactive isotope Cu-labeled drug which is a sterile non-pyrogenic sealed form of a solution, frozen, or lyophilized state, including 1 ng to 100 mg of the probe for detecting hydrogen sulfide including the radioactive isotope Cu-introduced complex compound or a pharmaceutically acceptable salt thereof.
- In an aspect of the present disclosure, the kit for preparing the drug is characterized by further including 0.01 mL-10 mL of a buffer solution at pH 1-9 and a concentration of 1 μM-10 μM.
- In another aspect of the present disclosure, the buffer solution is characterized by acetic acid, phosphoric acid, citric acid, fumaric acid, butyric acid, succinic acid, tartaric acid, carbonic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glucaric acid, boric acid, or a sodium salt or potassium salt thereof.
- According to still another aspect of the present disclosure, disclosed is a method of early diagnosing a disease in an animal excluding a human by examining whether a hydrogen sulfide concentration is rapidly increased or decreased as compared with that of a normal state by measuring the hydrogen sulfide concentration in the blood or tissue using the radioactive isotope Cu-introduced complex compound.
- Hereinafter, the present disclosure will be described in more detail with reference to Examples, etc. However, these examples should not be construed as narrowing or limiting the scope and content of the present disclosure. Further, it will be apparent that a person of ordinary skill in the art can easily implement the present invention, of which specific experimental results are not suggested, on the basis of the disclosure of the present invention including the following Examples, and changes and modifications also belong to the scope of the appended claims of the present invention.
- Synthesis of Various Chelates
-
- Cyclen (240 mg, 1.4 mmol) was added to a stirred solution of glucose (50 mg, 0.28 mmol) in anhydrous MeOH (10 mL), and the resulting solution was heated under reflux for 16 hours under N2 atmosphere. Complete consumption of the starting materials was confirmed by TLC [stationary phase=C-18 TLC, mobile phase=MeOH:10% NH4OAc (1:1)]. Then, the solvent was evaporated to dryness under reduced pressure and column chromatography was used to obtain a pure compound (52 mg, 56%). 1H NMR (D2O, 400 MHz): δ 1.8 (s, 3H), 2.60-3.02 (m, 17H), 3.24-3.42 (m, 6H), 3.58-3.63 (m, 1H), 3.78 (d, J=12.0 Hz, 1H), 4.00 (d, J=8.4 Hz, 1H); 13C NMR (D2O, 100 MHz): 543.67, 44.97, 45.92, 46.85, 49.18, 61.08, 69.96, 70.29, 77.47, 91.69; HRMS (FAB): m/z calcd for C14H30N4O5 [M+H] 335.2294; found 335.2296.
-
- K2CO3 (300 mg, 2.2 mmol) and ethyl 3-bromopropanoate (100 mg, 0.61 mmol) were added to a stirred solution of cyclen (380 mg, 2.2 mmol) in anhydrous CH3CN (10 mL), and the resulting solution was stirred at room temperature for 16 hours under N2 atmosphere. Complete consumption of the starting materials was confirmed by TLC [stationary phase=Basic alumina TLC, mobile phase=CH2Cl2:MeOH (10:1)]. The resulting product was separated from K2C03 by filtration, and evaporated to dryness under reduced pressure. Column chromatography was used to obtain a pure compound (100 mg, 64%). 1H NMR (CDCl3, 400 MHz): δ1.27 (t, J 7.2 Hz, 3H), 2.38-2.57 (m, 10H), 2.64-2.67 (m, 4H), 2.76-2.84 (m, 6H), 4.07-4.18 (m, 2H); 13C NMR (CDCl3, 100 MHz): δ14.10, 32.55, 44.38, 45.64, 46.39, 49.61, 50.92, 60.31, 172.67.
-
- K2CO3 (400 mg, 2.9 mmol) and 9-(chloromethyl)anthracene (655 mg, 2.9 mmol) were added to a stirred solution of cyclen (100 mg, 0.58 mmol) in anhydrous toluene (15 mL), and the resulting solution was heated under reflux for 16 hours under N2 atmosphere. Formation of a new product was confirmed by TLC [stationary phase=Silica TLC, mobile phase=EtOAc]. The resulting product was evaporated to dryness under reduced pressure and dichloromethane (50 mL) was added. The resulting product was shaken well with water and the separated organic layer was dried over MgSO4. Column chromatography was used to obtain a pure compound (270 mg, 50%). 1H NMR (CDCl3, 400 MHz): δ2.42 (s, 16H), 4.45 (s, 8H), 7.43-7.65 (m, 16H), 7.81-8.09 (m, 10H), 8.32-8.48 (m, 10H); 13C NMR (CDCl3, 100 MHz): δ45.28, 51.02, 54.68, 123.86, 124.60, 125.15, 126.52, 126.82, 127.38, 128.44, 129.31, 129.51, 131.44, 131.49, 131.51, 134.28.
-
- Chloromethylanthracene (1.0 equiv.) was dissolved in toluene (5 mL), and cyclen (5.0 equiv.) was added thereto. The resulting solution was heated under reflux for 8 hours. 1H NMR (CDC3, 400 MHz): δ2.04 (s, 3H, NH), 2.44-2.47 (m, 8H), 2.84-2.94 (m, 8H), 4.75 (s, 2H), 7.46-7.59 (m, 4H), 8.01-8.03 (m, 2H), 8.45-8.51 (m, 3H).
-
- Dansyl chloride (1.0 equiv.) was dissolved in toluene (5 mL), and then cyclen (5.0 equiv.) was added thereto. The resulting solution was stirred at room temperature for 2 hours. Precipitated salts were removed, and an organic phase was separated and dried. The solid was purified by column chromatography. 1H NMR (CDCl3, 400 MHz): δ2.00-2.04 (m, 3H), 2.89 (s, 6H), 3.11-3.88 (m, 16H), 7.20 (d, J=7.6 Hz, 1H), 7.50-7.59 (m, 2H), 7.92 (d, J=7.2 Hz, 1H), 8.34 (d, J=8.4 Hz, 1H), 8.57 (d, J=8.8 Hz, 1H)); 13C NMR (CDCl3, 100 MHz): 545.47, 47.37, 49.95, 50.74, 51.90, 115.67, 118.90, 123.12, 127.97, 128.75, 130.28, 130.56, 131.03, 132.84, 152.07.
-
- Step I: 3-thia-1,5-pentanedithiol (a, 1 equiv.) in DMF and N-boc-bis(2-chloroethyl)amine (b, 1 equiv.) were slowly added and Cs2CO3 (1.5 equiv.) was also added, and allowed to react for 96 hours at 65° C. to prepare N-Boc-[12]aneNS3 (c). The solvent was removed under vacuum, and the resulting product was dissolved in CH2Cl2 and washed with water to remove cesium salts. The product was dried over MgSO4, and subjected to filtration and evaporation processes. The resulting product was purified by recrystallization with warm toluene to obtain a white crystal of Nboc-[12]aneNS3 (c).
- Step II: N-Boc-[12]aneNS3 (c) was deprotected with a mixture of TFA and CH2Cl2 (1:1) at room temperature for 15 minutes. Excess TFA and CH2Cl2 were evaporated, and then water was added, and pH of the resulting product was adjusted to 14 by using Na2CO3 and NaOH. Thereafter, the mixture was extracted with CH2Cl2, and dried over MgSO4, and subjected to filtration and evaporation processes to obtain a white crystal of [12]aneNS3. 1H NMR (CDCl3, 400 MHz): δ2.71-2.91 (m, 16H), 3.98 (brs, 1H); 13C NMR (CDCl3, 100 MHz): δ 49.75, 32.37, 31.83, 31.56.
-
- Step I: Semicarbazide (1.0 equiv.) and 2,3-butadione (10 equiv.) were first mixed in MeOH (10 mL), and the resulting product was refluxed for 1 hour to obtain a compound c, which was then purified by column chromatography.
- Step II: The compound c (1 equiv.) was first mixed with hydrazine hydrate (10 equiv.) in MeOH (10 mL), and then the resulting product was refluxed for 1 hour to obtain a compound d, which was then purified by column chromatography.
- Step III: The compound d (1 equiv.) was first mixed with N,N-dimethyl urea (1 equiv.) in MeOH (10 mL), and then the resulting product was refluxed for 1 hour to obtain a compound f. The solvent was dried and the compound f was purified by column chromatography to obtain a pure compound f. 1H NMR (DMSO-de, 400 MHz): δ1.574 (s, 1H), 1.85 (s, 1H), 1.95 (s, 1H), 2.02 (s, 3H), 2.19 (s, 6H), 3.03 (s, 3H), 3.04 (s, 3H), 3.13 (s, 1H).
-
- Potassium carbonate (27 mg, 0.19 mmol) and methyl iodide (28 mg, 0.19 mmol) were added to a stirred solution of TACN (100 mg, 0.78 mmol) in anhydrous acetonitrile (10 mL), and the resulting solution was stirred at room temperature for 16 hours. Formation of a new product was confirmed by TLC [stationary phase=Silica TLC, mobile phase=dichloromethane:IPA (10:1)]. The product was diluted with acetonitrile, and separated from potassium carbonate by using a filter, and evaporated to dryness under reduced pressure to obtain 1-methyl-1,4,7-triazonane. HR-MS (FAB) m/z calculated value C7H17N3 [M+H]+ 144.1501, measured value 144.1501.
-
- Potassium carbonate (27 mg, 0.19 mmol) and 9-(chloromethyl)anthracene (43 mg, 0.19 mmol) were added to a stirred solution of TACN (100 mg, 0.78 mmol) in anhydrous acetonitrile (10 mL), and the resulting mixture was stirred at room temperature for 16 hours. Formation of a new product was confirmed by TLC [stationary phase=Silica TLC, mobile phase=dichloromethane:IPA (10:1)]. The product was diluted with acetonitrile, and separated from potassium carbonate by using a filter, and evaporated to dryness under reduced pressure to obtain 1-(anthracen-9-ylmethyl)-1,4,7-triazonane. HR-MS(FAB) m/z calculated value C21H25N3[M+H]+ 320.2127, measured value 320.2127.
-
- Potassium carbonate (27 mg, 0.19 mmol) and 1-bromohexadecane (58 mg, 0.19 mmol) were added to a stirred solution of TACN (100 mg, 0.78 mmol) in anhydrous acetonitrile (10 mL), and the resulting solution was stirred at room temperature for 16 hours. Formation of a new product was confirmed by TLC [stationary phase=Silica TLC, mobile phase=dichloromethane:IPA (10:1)]. The product was diluted with acetonitrile, and separated from potassium carbonate by using a filter, and evaporated to dryness under reduced pressure to obtain 1-hexadecyl-1,4,7-triazonane. HR-MS(FAB) m/z calculated value C22H47N3[M+H]+ 354.3848, measured value 354.3848.
-
- Potassium carbonate (433 mg, 3.12 mmol) and methyl iodide (443 mg, 3.12 mmol) were added to a stirred solution of TACN (100 mg, 0.78 mmol) in anhydrous acetonitrile (10 mL), and the resulting solution was stirred at room temperature for 16 hours. Formation of a new product was confirmed by TLC [stationary phase=Silica TLC, mobile phase=dichloromethane:IPA (10:1)]. The product was diluted with acetonitrile, and separated from potassium carbonate by using a filter, and evaporated to dryness under reduced pressure to obtain 1,4,7-trimethyl-1,4,7-triazonane. MS(FAB) m/z calculated value C9H21N3[M] 171.17, measured value 171.11
-
- Potassium carbonate (433 mg, 3.12 mmol) and 9-(chloromethyl)anthracene (705 mg, 3.12 mmol) were added to a stirred solution of TACN (100 mg, 0.78 mmol) in anhydrous acetonitrile (10 mL), and the resulting solution was stirred at room temperature for 16 hours. Formation of a new product was confirmed by TLC [stationary phase=Silica TLC, mobile phase=dichloromethane:IPA (10:1)]. The product was diluted with acetonitrile, and separated from potassium carbonate by using a filter, and evaporated to dryness under reduced pressure to obtain 1,4,7-tris(anthracen-9-ylmethyl)-1,4,7-triazonane. HR-MS(EI) m/z calculated value C51H45N3[M]+699.3613, measured value 699.3612.
-
- Potassium carbonate (433 mg, 3.12 mmol) and 1-bromohexadecane (949 mg, 3.12 mmol) were added to a stirred solution of TACN (100 mg, 0.78 mmol) in anhydrous acetonitrile (10 mL), and the resulting solution was stirred for 16 hours. Formation of a new product was confirmed by TLC [stationary phase=Silica TLC, mobile phase=dichloromethane:IPA (10:1)]. The product was diluted with acetonitrile, and separated from potassium carbonate by using a filter, and evaporated to dryness under reduced pressure to obtain 1,4,7-trihexadecyl-1,4,7-triazonane. HR-MS(EI) m/z calculated value C54H111N3 [M+H]+ 802.8856, measured value 802.8856.
- Radioactive labeling of various chelates with 64Cu
- 64CuCl2 of 0.01 N HCl (1-2 L, 1-5 mCi) was added to various chelates (100 μg) dissolved in 100 μL of 0.1 M ammonium acetate (pH=6.8) without addition of carriers, and allowed to react for 20 minutes at 60° C. to prepare different kinds of chelate-64Cu complexes (of the chelates, PCB cyclam which is a complex compound of the following Example 19 was reacted for 60 minutes at 90° C.). A chelate storage solution (20 μg/μL) was prepared by using MilliQ water (the following Example 19) or anhydrous DMSO (Examples 24, 25, 33, 34, 17, a mixture of 18 and 18-1, 26, and 23). Corresponding Cu complex formation was confirmed by radio-TLC. Radioactive isotope-labeled compounds for Example 17 and a mixture of Example 18 and 18-1 were purified by using a C-18 Sep Pak column (washed with 10 mL of water to remove DMSO, the compound was eluted with 200 μL of EtOH six times).
-
- 0.01 mg-2 mg of 1,4,7,10-tetraazacyclododecane was dissolved in a buffer solution of 0.1 M NH4OAc (pH 6.8) and then 10 μCi-10,000 μCi of 64CuCl2 solution was added thereto, and allowed to react at 60° C. to prepare a 64Cu complex compound represented by Chemical Formula 1a. If the chelate was not dissolved well, a small amount of DMSO was used.
- A labeling yield of the 64Cu complex compound represented by Chemical Formula 1a was confirmed by radio-TLC, and the results are shown in the following Table 1.
-
TABLE 1 (mm) (mm) (mm) Region Region % of % of Reg Start Stop Centroid Rf counts CPM Total ROI Rgn 1 48.2 73.1 62.2 0.271 167686.0 83843.0 97.67 100.00 1 — — — — 167686.0 83843.0 97.67 100.00 peaks - As shown in Table 1, labeling of 1,4,7,10-tetraazacyclododecane with 64Cu was found to be 100%.
-
- A 64Cu complex compound represented by Chemical Formula 1b was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1c was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1d was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1e was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1f was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1g was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by
Chemical Formula 1 h was obtained in the same manner as in Example 1. -
- A 64Cu complex compound represented by Chemical Formula 1i was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1j was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1k was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1l was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1m was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1n was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1o was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1p was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1q was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1r was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1r′ was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1s was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 2a was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 2b was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 2c was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1t was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 1u was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by
Chemical Formula 4 was obtained in the same manner as in Example 1. -
- A 64Cu complex compound represented by Chemical Formula 1w was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 2d was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 2e was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 2f was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 2g was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by
Chemical Formula 2h was obtained in the same manner as in Example 1. -
- A 64Cu complex compound represented by Chemical Formula 2i was obtained in the same manner as in Example 1.
-
- 64Cu complex compound represented by Chemical Formula 3a was obtained in the same manner as in Example 1.
-
- A 64Cu complex compound represented by Chemical Formula 3b was obtained in the same manner as in Example 1.
- To measure hydrogen sulfide detection sensitivity of the 64Cu-labeled complex compound according to the present disclosure, the following experiment was performed. Results are shown in the following Tables 2 and 3, and
FIG. 1 . - About 45 μCi-55 μCi of 64Cu-labeled complex compound (250 μL of triple distilled water) was mixed with various concentrations of NaHS solution (250 L of triple distilled water), and stirred at 37° C. for 15 minutes (a total volume used in the reaction was equally 500 μL). After completion of the reaction, the resulting products were strongly stirred to mix appropriately.
- Formation of copper sulfide (64CuS) was confirmed by quantification of % decomplexation by using a radio-TLC scanner, and results are shown in the following Tables 2 and 3.
-
TABLE 2 Example 2 cyclen- NaHS Example 1 Anthracene Example 3 Example 23 Example 16 Example 20 Example 21 (μM) cyclen (1:1) DODACD ATTCD cyclam TACN TACD 0 0 0 0 0 0 0 0 1 3 0 0 0 0 0 0 10 11 0 3 0 0 9 6.2 15 63 0 6 36.4 0 11 10 20 95 15 79 49.4 0 13.5 58 50 100 56 100 67.7 1.3 24.6 63 100 100 100 100 78.2 10.5 54.4 100 -
TABLE 3 % decomplexation against Example 100 μM NaHS solution 24 0 25 0 33 26.6 34 0 17 39.67 26 62.43 ± 0.87 23 78.3 ± 2.6 - As shown in Tables 2 and 3, the results of measuring the lowest detectable concentration of hydrogen sulfide by the 64Cu-labeled complex compound according to the present disclosure showed that 64Cu-labeled cyclen of Example 1 according to the present disclosure has the lowest detection limits from low concentrations to high concentrations, and it has the most excellent sensitivity for hydrogen sulfide.
- As shown in
FIGS. 2A and 2B , radio-TLC results of using 64Cu-labeled cyclen of Example 1 according to the present disclosure at different concentrations of sulfide ion showed that 64Cu-labeled cyclen of Example 1 had Rf value greater than 0, but when 64Cu-labeled cyclen of Example 1 reacts with sulfide ions to form 64CuS, its Rf value was changed to 0, and it remained at a starting point without moving, and therefore, reaction was easily detected. - To examine reactivity of the 64Cu-labeled complex compound according to the present disclosure over time, the following experiment was performed. Results are shown in the following Table 4 and
FIG. 3 . - A detailed experimental method is as follows.
- About 45 μCi-50 μCi of 64Cu-labeled complex compound (250 μL of triple distilled water) was mixed with 100 μM of NaHS solution (250 mL of triple distilled water), and stirred at 37° C. for 15 minutes. Formation of copper sulfide (64CuS) was quantified by using a radio-TLC scanner.
-
TABLE 4 Section 10 sec 30 sec 60 sec 5 min 10 min 15 min Example 1 cyclen 13 17 21 100 100 100 Example 2 cyclen- 21 22 33 82 100 100 Anthracene Example 3 DODACD 62 70 75 100 100 100 Example 16 cyclam 0 0 0 3 5 10 Example 20 TACN 0 0 5 13 60 60 Example 21 TACD 52 72 100 100 100 100 - As shown in Table 4, to examine a reaction rate of the 64Cu-labeled complex compound according to the present disclosure with sulfide ions, hydrogen sulfide concentrations were measured over time. As a result, 64Cu-labeled complex compounds of Examples 1, 2, 3 and 21 were found to begin to detect hydrogen sulfide within about 10 seconds.
- In addition to hydrogen sulfide, many different anions, radicals, etc. exist in the body. Therefore, to examine selective reactivity of the 64Cu-labeled complex compound according to the present disclosure for sulfide ions, the following experiment was performed. Results are shown in the following Table 5.
- About 45 μCi-55 μCi of the 64Cu-labeled complex compound (250 μL of triple distilled water) was mixed with 100 μM of various anion solutions (250 μL of triple distilled water) including biothiol, and stirred at 37° C. for 15 minutes.
- Formation of copper sulfide (64CuS) was quantified by using a radio-TLC scanner.
- Various biothiol or salt solutions were prepared by dissolving the compounds in triple distilled water.
-
TABLE 5 Decomplexation [%] Example 20 Example 1 Example 16 Example 3 Example 23 Example 21 64Cu-TACN 64Cu-cyclen 64Cu-cyclam 64Cu-DODACD* 64Cu-AATTCD 64Cu-TACD* Cys 0.8 ± 0.3 0.5 ± 0.1 0.7 ± 0.2 0.4 0.5 9 ± 3 Hcys 1.1 ± 0.5 1.4 ± 0.4 0.7 ± 0.0 27 ± 3 0.4 30 ± 5 GSH 2.6 ± 0.0 0.7 ± 0.0 0.8 ± 0.2 48 0.7 33 DTT 0.9 ± 0.1 0.6 ± 0.4 0.8 ± 0.0 45 ± 2 0.4 25 L-Asa 0.8 ± 0.5 0.5 ± 0.1 0.7 ± 0.2 15 0.4 4 ± 2 ME 0.4 ± 0.0 0.5 ± 0.1 0.5 ± 0.6 16 0.5 2 ± 2 NaCl 0.5 ± 0.0 0.2 ± 0.0 0.7 ± 0.0 0.3 0.5 0.4 ± 0.2 Kl 0.4 ± 0.2 0.7 ± 0.2 0.7 ± 0.0 0.1 0.2 0.3 Na2S2O3 0.5 ± 0.0 0.4 ± 0.0 0.8 ± 0.1 19 ± 5 0.2 3 ± 1 Na2S2O5 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.0 5 0.6 4 ± 2 NaOAc 0.3 ± 0.0 0.6 ± 0.1 0.8 ± 0.0 15 0.3 1 H3O2 0.8 ± 0.3 0.5 ± 0.4 0.7 ± 0.2 0.4 0.3 3 NaClO4 0.4 ± 0.1 0.6 ± 0.2 0.6 ± 0.1 0.4 0.8 2 ± 1 NaHCO3 0.6 ± 0.4 0.6 ± 0.3 0.5 ± 0.1 0.3 0.1 0.9 NaNO2 0.4 ± 0.0 0.6 ± 0.0 0.5 ± 0.1 0.5 0.6 0.5 NaN3 0.4 ± 0.0 0.3 ± 0.2 0.7 ± 0.1 0.6 0.8 0.5 ATB 337 0.7 ± 0.2 0.7 ± 0.4 0.6 ± 0.0 3 ± 1 0.6 6 ± 2 DAT 0.7 ± 0.6 0.4 ± 0.3 0.5 ± 0.1 100 0.4 49 ± 2 - In Table, concentrations of all biothiols and other competitive materials are 100 μM. Further, specific concentrations of biothiols, anions, and oxidants used in Table are as follows: [L-Cys (1 mM); L-Hcys (10 mM); GSH (10 mM); DL-dithiothretitol (DTT, 100 μM); L-ascorbic acid (L-AsA, 10 mM); 2-mercaptoethanol (2-ME, 10 mM); NaCl (10 mm); Kl (1 mM); Na2S2O3 (1 mM); Na2S2O5 (1 mM); NaOAc (1 mM); H2O2 (100 M); NaClO4 (100 μM); NaHCO3 (100 μM); NaNO2 (100 M); NaN3 (100 μM); ATB 337 (100 μM); diallyl trisulphide (100 μM)].
- As shown in Table 5, results of measuring reactivity with various anions containing sulfur showed that 64Cu-labeled complex compounds of Examples 1, 2, 16 and 20 according to the present disclosure selectively reacted with hydrogen sulfide whereas 64Cu-labeled complex compounds of Examples 3 and 21 did not selectively react with hydrogen sulfide, and they also reacted with other biothiol compounds or anions.
- Further, selective reactivity of radioactive isotope copper ions, which were not labeled with chelates, with hydrogen sulfide was examined. As a result, it was found that the copper ions reacted with various biothiol compounds or anions, unlike 64Cu-labeled cyclen of Example 1 according to the present disclosure.
- Cellular drug uptake is an important prognostic factor in the diagnosis of diseases. Therefore, to examine cellular uptake of the 64Cu-labeled complex compounds according to the present disclosure, experiments for measuring changes in the cellular uptake under various concentrations of hydrogen sulfide were performed.
- A colon carcinoma cell CT-26 was seeded in each plate at a density of 5×106, and then 10 μCi-300 μCi of 64Cu-labeled complex compound of Examples 1, 7 or 9 according to the present disclosure was treated thereto, followed by incubation for 10 minutes. The cells were washed with PBS, and then 0 μM, 1 μM, or 50 μM of NaHS solution was added thereto, followed by incubation for 5 minutes. Thereafter, the cells were washed with PBS, and then cells were removed from the plate by adding trypsin and EDTA, followed by centrifugation. Supernatants were discarded and radiation of remaining cells was measured by using a gamma counter.
- Results are shown in the following Table 6.
-
TABLE 6 Section Concentration (μM) Uptake Example 1 0 600 1 780 50 850 Example 7 0 20000 1 21000 50 23000 Example 9 0 7000 1 6500 50 6900 Example 20 0 30000 1 32000 50 34000 - As shown in Table 6, 64Cu-labeled complex compounds according to the present disclosure showed that as the NaHS concentration was increased, radiation of 64Cu-labeled complex compounds by cellular uptake slightly increased.
- In order to examine whether the 64Cu-labeled complex compounds according to the present disclosure are able to selectively detect in vivo hydrogen sulfide, different materials were injected into the backs of rats, and then each 64Cu-labeled complex compound according to the present disclosure was injected via the tail, and then selective imaging was examined by optical imaging.
-
FIG. 4 shows photographs of examining selective imaging through optical imaging after injecting the backs of rats with 64Cu-labeled complex compounds according to the present disclosure. Referring toFIG. 4 , at the beginning of the first experiment, matrigel alone, matrigel+1 mg NaCl, matrigel+0.5 mg NaHS, and matrigel+0.05 mg NaHS were injected into four sites on the backs of rats, respectively. 1.8 mCi of the 64Cu-labeled complex compound according to Example 1 was injected via the tails of rats, immediately followed by optical imaging. As a result, of the four sites, signals were detected only in the lower two sites injected with NaHS generating hydrogen sulfide. Even after 4 hours, signals were still detected only in the lower two sites. - Next, at the beginning of the second experiment, about 0.48 mCi of Cu(II) ion, 64CuS, 64Cu-labeled complex compound according to Example 1, and 64Cu-labeled complex compound according to Example 16 were injected into four sites on the backs of the same rats, respectively. Immediately, optical images were taken and shown in a lower left image of
FIG. 4 . A photograph taken after 4 hours was shown in a lower right image ofFIG. 4 . Referring toFIG. 4 , 64Cu-labeled complex compound according to Example 1 and 64Cu-labeled complex compound according to Example 16 were very rapidly excreted from the body, unlike 64CuS. A retention time of 64Cu(II) ion was about half of 64CuS. These experiments showed that the 64Cu-labeled complex compounds according to the present disclosure bind with hydrogen sulfide to form 64CuS, which remains for a long time in the body, thereby being easily detected by imaging. - (1) Paw Pain Inflammation Model
- A small amount of CFA (complete Freund's adjuvant) or formalin was injected into only one paw (right) of the hind paws of Balb/c or ICR mice to establish inflammation models. 1 day after injection of the inflammation inducer, the mice were used in imaging or other in vivo experiments.
- It is a known fact that inflamed sites show high concentrations of hydrogen sulfide.
- (2) Myocardial Infarction Model
- A myocardial infarction model was established by using Sprague-Dawley rats (12-week-old or older, about 250 g). 2 days later after induction of myocardial infarction by occlusion of the coronary arteries in the heart, the rats were used in imaging tests. It is a known fact that myocardial infarction sites show high concentrations of hydrogen sulfide.
- (3) Arthritis Model
- An arthritis inducer, bovine type II collagen was intradermally injected into the tails of DBA/1J mice twice, and 5 weeks later (about 13-week-old), the mice were used in imaging tests. Arthritis degree of the paw was quantified by scoring.
- (4) Brain Inflammation Model
- An inflammation inducer, lipopolysaccharide was directly injected into one part of the brain of Sprague-Dawley rat to induce inflammation in one part of the brain. 24 hours after induction of inflammation, the rats were used in imaging tests.
- (5) Tumor Model
- To prepare a CT26 tumor model, the number of cells was counted using a haemacytometer, and 5×106 cells were subcutaneously injected into the right flank of BALB/c mouse. About 10 days later, when formation of about 1 cm of tumor was observed, the mice were used in subsequent experiments.
- To prepare an EMT6 tumor model, the number of cells was counted using a haemacytometer, and 2×105 cells were subcutaneously injected into the right flank and left shoulder region of BALB/c female mouse. About 2-3 weeks later, when formation of about 1 cm of tumor was observed, the mice were used in subsequent experiments.
- (6) Sepsis Model
- After the lower abdominal region of ICR mice was opened, a small puncture in the appendix was made by using a syringe needle to prepare an acute sepsis model.
- (7) Brain Tumor Model
- The surface of the rat's head was incised and the capillaries and meninges on the outer surface of the skull were removed. Subsequently, a hole was made at the defined coordinates by stereotactic surgery, and 20,000 C6 cells which are known as glioma cells of the rat brain were injected by using a syringe pump. After cell injection, the syringe was left for about 5 minutes to allow absorption of the cells, and then slowly removed. The hole was filled with bone cement, and then sutured to prepare a brain tumor model.
- (8) Pancreatitis Model
- Caerulein (50 μg/kg) was intraperitoneally injected into Balb/c mouse seven times at hourly intervals to prepare a pancreatitis model.
- Nuclear medicine imaging was measured by using an Inveon PET/CT system of Siemens Healthcare, and optical imaging was measured by using IVIS spectrum CT equipment. Cherenkov radiation emitted from 64Cu was measured by using a highly sensitive CCD (charge-coupled device) camera.
- Imaging was measured for 1 minute to 5 minutes, and a radiation dose was about 50 μCi to 2000 μCi, and photographs were variously taken as needed, such as immediately after first injection, at 1 hour, 4 hours, and 24 hours later.
- (1) Paw Inflammation Model
- As shown in
FIG. 5A , result of treating 64Cu-labeled cyclen of Example 1 according to the present disclosure showed that higher uptake in the inflamed right paw than in the opposite paw was observed in PET imaging. As shown inFIG. 5B , optical imaging showed increased uptake of 64Cu-labeled cyclen of Example 1 according to the present disclosure in the CFA-induced inflamed site. As shown inFIG. 5C , it was confirmed that 64Cu-labeled cyclen of Example 1 according to the present disclosure showed a high reaction rate with hydrogen sulfide such that the inflamed site can be detected immediately after injection (1.5-10 minutes). - As shown in
FIG. 5D , the same results were also observed in the paw inflammation ICR and Balb/c mouse models, and 64Cu-labeled cyclen of Example 1 according to the present disclosure showed a retention time of 24 hours or longer in the animal models, suggesting that therapeutic effects may be predicted in a non-invasive manner without continuous injection of the drug. - As shown in
FIGS. 6A to 6C , higher uptake of 64Cu-labeled TACN of Example 20 was observed in the inflamed paw than in the opposite paw when imaging was performed after 1 hour, and the same result was also observed in PET imaging. The inflamed site was also detected in imaging immediately after injection of 64Cu-labeled TACN of Example 20. - In addition, selective uptake of 64Cu-labeled complex compound of Examples 2, 3, 14 or 21 according to the present disclosure in inflamed sites was also observed in optical imaging and nuclear medicine imaging, as shown in
FIGS. 7A to 7D andFIGS. 8A to 8E . - Meanwhile, as shown in
FIGS. 9A to 9B andFIGS. 10A to 10B , higher uptakes of 64Cu-labeled compounds 1 g and 1i of Examples 7 and 9 in the inflamed paw than in the opposite paw were observed in the optical and nuclear medicine imaging which were performed 2 hours later. - Meanwhile, as shown in
FIGS. 11A to 11D , 64Cu-labeled cyclam of Example 16 showed no obvious difference in the inflamed and normal paws, and its injection showed low uptake, compared to injection of the same quantity of 64Cu-labeled cyclen of Example 1. - (2) Arthritis Model
- When 64Cu-labeled cyclen of Example 1 according to the present disclosure was injected into the arthritis model, selective uptake in the joint region was observed, as shown in
FIGS. 13A and 13B . - (3) Brain Inflammation Model
- Inflammation was induced by injecting LPS into the half of the rat's brain, and 1 day later, 64Cu-labeled complex compound of Example 17 according to the present disclosure was injected, followed PET imaging. As shown in
FIG. 14 , higher uptake was observed in the inflamed site than in the opposite site. - It is known that myocardial infarction sites show high concentrations of hydrogen sulfide. Thus, after induction of myocardial infarction by coronary artery occlusion in rats, 50 μCi-900 μCi of the 64Cu-labeled complex compound was injected via the tails of the rats, and uptake in the myocardial infarction site was examined over time by PET imaging.
- 2 days after injection of the 64Cu-labeled complex compound, [18F]FDG was injected, and PET imaging was performed to examine whether myocardial infarction was properly induced.
- 36 hours after establishment of the myocardial infarction model, 730 μCi of the radioisotope-labeled complex compound of the present disclosure was injected and nuclear medicine imaging was performed. 2 days later, 1.06 μCi of FDG was injected into the same rat, and then FDG-PET images were obtained. Results are shown in
FIGS. 15 to 17 (in the nuclear medicine imaging, the upper image represents a transverse image, and the lower image represents a coronal image). - As shown in
FIG. 15 , in the image taken at 24 hours after injection of Cu-labeled cyclen of Example 1 according to the present disclosure, high uptake was detected in the myocardial infarction site such that the myocardial infarction site was clearly observed. In contrast, when FDG was injected, FDG uptake did not occur in the myocardial infarction site, and therefore, the cardiac muscles was observed not as donut-shaped rings but as partially broken rings. - As shown in
FIG. 16 , when 64Cu-labeled TACN compound of Example 20 was injected, the myocardial infarction site was clearly observed. - As shown in
FIG. 17 , when 64Cu-labeled cyclam of Example 16 was injected, no specific uptake was observed in the heart, as in the above paw inflammation and arthritis models. - PET images were obtained at 72 hours after injecting the 64Cu-labeled 1q compound of Example 17 into the prepared brain tumor rat model. High uptake was observed in the brain tumor, and this imaging study suggests that brain tumor may be diagnosed by using the probe for detecting hydrogen sulfide.
- PET images were obtained after injecting the 64Cu-labeled complex compound of Example 1 into the prepared rat model having EMT6 tumor and rat model having CT26 tumor. Results are shown in
FIGS. 19A and 19B . Referring toFIGS. 19A and 19B , higher uptake was observed in the tumor region (red circle) than in the background, suggesting that the probe for detecting hydrogen sulfide may be used in the diagnosis of various tumors. In particular, since EMT6 tumor is commonly used as a hypoxic tumor model, the probe may be suggested as a probe applicable to detection of hypoxia in tumors. - Optical images were obtained after injecting each of the 64Cu-labeled complex compounds of Example 1 and Example 20 into the prepared rat models having pancreatitis, and PET images were obtained after excision of tissues thereof. Results are shown in
FIG. 20 . Referring toFIG. 20 , high uptakes of the Cu-labeled complex compounds of Example 1 and Example 20 were observed in the pancreas (red oval) of the pancreatitis models, suggesting that the probe of the present disclosure may be used to diagnose pancreatitis. - PET images were obtained after injecting the 64Cu-labeled complex compound of Example 20 into the prepared rat model having sepsis. Result is shown in
FIG. 21 . Referring toFIG. 21 , uptake was increased throughout the body of the sepsis model. In particular, increased uptake was observed in the lung, suggesting that the probe for detecting hydrogen sulfide may be used in the diagnosis of sepsis. - PET images were obtained after injecting the 64Cu-labeled complex compound of Example 1 into a normal rat, and PET images were obtained again after excision of the tongue thereof. Results are shown in
FIG. 22 . In PET image before excision of the tongue (A), high uptake was observed in the tongue. However, after excision (B), the uptake was decreased in the same site. Further, high uptake was observed in the tongue removed by excision. (C) is a photograph taken before imaging the tongue after excision. These results suggest that the probe for detecting hydrogen sulfide may be used in the detection of hydrogen sulfide under a normal condition as well as under a disease condition. - 64Cu-labeled TACN of Example 20 according to the present disclosures was reacted with various concentrations of NaHS which is a source of hydrogen sulfide, and decomplexation was measured to obtain a calibration curve, as shown in
FIG. 23 . There was a very excellent correlation therebetween, suggesting that concentrations of hydrogen sulfide may be accurately determined by measuring decomplexation. - In order to demonstrate that the complex compound for detecting hydrogen sulfide according to the present disclosure specifically detects a model having a specific disease showing a higher concentration of hydrogen sulfide than a normal rat, data obtained by using the 64Cu-labeled complex compound of Example 20 and a common methylene blue method were compared.
- The obtained data were shown in the following Table 7 and
FIG. 24 . -
TABLE 7 Normal Standard Myocardial Standard rat deviation infarction model deviation 64Cu-TACN 23.6 3.9 41.8 2.0 Methylene blue 23.8 7.0 40.3 2.0 - Referring to Table 7 and
FIG. 24 , the complex compound for detecting hydrogen sulfide according to the present disclosure may specifically detect a myocardial infarction model generating hydrogen sulfide, which is comparable to the common methylene blue method.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/730,029 US20200138982A1 (en) | 2015-04-07 | 2019-12-30 | Radioactive probe for detecting hydrogen sulfide |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0049305 | 2015-04-07 | ||
KR1020150049305A KR20150116421A (en) | 2014-04-07 | 2015-04-07 | Radioactive probe for detecting hydrogen sulfide |
PCT/KR2016/003559 WO2016163727A2 (en) | 2015-04-07 | 2016-04-06 | Radioactive probe for detecting hydrogen sulfide |
US15/564,214 US10583206B2 (en) | 2014-04-07 | 2016-04-06 | Radioactive probe for detecting hydrogen sulfide |
US16/730,029 US20200138982A1 (en) | 2015-04-07 | 2019-12-30 | Radioactive probe for detecting hydrogen sulfide |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/564,214 Division US10583206B2 (en) | 2014-04-07 | 2016-04-06 | Radioactive probe for detecting hydrogen sulfide |
PCT/KR2016/003559 Division WO2016163727A2 (en) | 2014-04-07 | 2016-04-06 | Radioactive probe for detecting hydrogen sulfide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200138982A1 true US20200138982A1 (en) | 2020-05-07 |
Family
ID=60937168
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/564,214 Active US10583206B2 (en) | 2014-04-07 | 2016-04-06 | Radioactive probe for detecting hydrogen sulfide |
US16/730,029 Abandoned US20200138982A1 (en) | 2015-04-07 | 2019-12-30 | Radioactive probe for detecting hydrogen sulfide |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/564,214 Active US10583206B2 (en) | 2014-04-07 | 2016-04-06 | Radioactive probe for detecting hydrogen sulfide |
Country Status (3)
Country | Link |
---|---|
US (2) | US10583206B2 (en) |
EP (1) | EP3281643A4 (en) |
WO (1) | WO2016163727A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107188801B (en) * | 2017-05-15 | 2020-05-05 | 天津大学 | Tetraphenyl ethylene ion complex-based divalent copper ion fluorescent probe and preparation method and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPP803899A0 (en) * | 1999-01-05 | 1999-01-28 | Australian National University, The | Cryptate compounds and methods for diagnosis and therapy. |
EP1322653A2 (en) * | 2000-09-25 | 2003-07-02 | The Procter & Gamble Company | Metal complexes for use in medical and therapeutic applications |
US20110027172A1 (en) * | 2007-12-10 | 2011-02-03 | Zhuang Wang | Drug delivery system for pharmaceuticals and radiation |
CN101780286A (en) * | 2009-01-16 | 2010-07-21 | 中国人民解放军总医院 | Chemotactic factor receptor CXCR4 non-peptide antagonist medicaments for radiodiagnosis and treatment |
KR101404369B1 (en) | 2012-08-14 | 2014-06-09 | 경희대학교 산학협력단 | A real-time bio-signal measurement device for cardiac ischemia - reperfusion |
-
2016
- 2016-04-06 WO PCT/KR2016/003559 patent/WO2016163727A2/en unknown
- 2016-04-06 EP EP16776830.8A patent/EP3281643A4/en active Pending
- 2016-04-06 US US15/564,214 patent/US10583206B2/en active Active
-
2019
- 2019-12-30 US US16/730,029 patent/US20200138982A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
Hai et al., Analytical Chemistry, 2015, p. 2678-2684. (Year: 2015) * |
Park et al., Nuclear Medicine and Biology, 2011, 38, p. 321 – 329. (Year: 2011) * |
Also Published As
Publication number | Publication date |
---|---|
US10583206B2 (en) | 2020-03-10 |
EP3281643A2 (en) | 2018-02-14 |
WO2016163727A3 (en) | 2017-03-23 |
WO2016163727A9 (en) | 2017-05-11 |
WO2016163727A2 (en) | 2016-10-13 |
EP3281643A4 (en) | 2018-12-26 |
US20180369428A1 (en) | 2018-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102214462B1 (en) | Radioactive probe for detecting hydrogen sulfide | |
JP7219497B2 (en) | PSMA binder and use thereof | |
US10039845B2 (en) | Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents | |
JP7449864B2 (en) | Chemical conjugates of Evans blue derivatives and their use as radiotherapy and contrast agents to target prostate cancer | |
RU2376282C2 (en) | Stereo-selective synthesis of amino acids for production of tumor image | |
US20200138982A1 (en) | Radioactive probe for detecting hydrogen sulfide | |
AU2015203742B2 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents | |
CA2911307C (en) | Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging | |
WO2023145967A1 (en) | Probe for nuclear medical testing | |
WO2023109745A1 (en) | SMALL-MOLECULE PROBE FOR IMAGING OF α-SYNUCLEIN AGGREGATE | |
US20220218851A1 (en) | Compounds and methods for imaging immune activity | |
KR20130089274A (en) | Nitroimidazole-amino acid compound type nuclide hypoxia imaging agent and intermediates for preparing them | |
JP2023554079A (en) | Ligands and their uses | |
KR20230111155A (en) | Dual-modality probe for the detection of hydrogen sulfide and uses thereof | |
KR20220146218A (en) | Tracer for PET Specific to beta-adrenergic receptor | |
WO2019056097A1 (en) | Markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |